4th European Conference on Schizophrenia · PDF fileTogether for better treatment and care ... on Schizophrenia to initiate this biennial European schizophrenia ... Speaker of the

Final Programme

www.schizophrenianet.eu

4th European Conference on Schizophrenia Research Together for better treatment and care

Joint thematic congress of the European Scientifi c Association on Schizophrenia and other Psychoses (ESAS), the Competence Network on Schizophrenia (CNS), the European Psychiatric Association (EPA), and German Association for Psychiatry, Psycho-therapy and Psychosomatics (DGPPN)

26 – 28 September 2013Berlin, Germany

World Psychiatric Association (WPA)and its Section on Schizophrenia

in cooperation with

WO

RLD

PSYCHIATRIC ASSOCIATION

www.wpanet.org

ASIAN NETWORK FOR

SCHIZOPHRENIARESEARCH

accredited by the European Council for Continuing Education

(EACCME) with 16 CME credits

2

TABLE OF CONTENT

Page

Welcome Address ....................................................................................................................................................................... 3

Conference Organisation ....................................................................................................................................................... 5

Conference Information ......................................................................................................................................................... 6

Format Descriptions / CME Credits ................................................................................................................................... 8

Opening Ceremony and Welcome Reception ........................................................................................................... 10

Overview Scientific Programme ....................................................................................................................................... 11

Scientific ProgrammeThursday, 26 September .........................................................................................................................................................14Friday, 27 September ...............................................................................................................................................................24Saturday, 28 September ........................................................................................................................................................40

Floorplan .......................................................................................................................................................................................50

Acknowledgements ................................................................................................................................................................. 51

Index Chairpersons, Authors and Presenters ...........................................................................................................52

3

WELCOME ADDRESS

Dear Colleagues,

In recent years a growing body of cutting-edge schizophrenia research was performed and new evidence was generated with regard to aetiology, symp-tomatology, treatment and care of schizophrenia. Treatment research on new pharmacological targets and novel mechanisms of action demonstrated encouraging efficacy across a range of symptoms allowing for a better and personalised treatment. New imaging techniques were developed to gain new insights in the pathophysiology of this disorder. Some recent findings may help to diagnose schizophrenia earlier in the course and to predict treatment response. Yet we are still far away from understanding the underlying causes and com-plexity of schizophrenia corresponding to heterogeneous patient needs. Publi-cation of the fifth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) earlier this year has led to an intense and controversial discussion beyond the psychiatric community becoming a matter of public interest and media coverage.

The scientific programme of the European Conference on Schizophrenia Research (ECSR) critically discusses recent scientific advances, deals with current contro-versies, and updates the scientific knowledge about schizophrenia and translate it into clinical practice. The need to have a forum for scientific exchange and to address clinical challenges encouraged, in 2007, the Competence Network on Schizophrenia to initiate this biennial European schizophrenia congress which will be held for the fourth time.

According to this year’s motto “Together for better treatment and care”, the scientific programme of the ECSR provides a comprehensive overview on recent research projects and developments in schizophrenia treatment and documents the broad range of topics to be presented in plenary lectures, (prearranged and submitted) symposia, workshops, oral presentations and poster sessions. Treat-ment of negative symptoms, deficits in social cognition, non-adherence, and the promotion and implementation of evidence-based strategies to ensure standards of care as well as basic research topics will be addressed by high quality contributions from acknowledged experts, young scientists, and clinicians.

4

WELCOME ADDRESS

As in previous years, the co-organising psychiatric associations and their respec-tive schizophrenia sections play an important role in this joint thematic confer-ence. On occasion of the third ECSR the European Scientific Association on Schizophrenia and other Psychoses (ESAS) took over the responsibility to orga-nise future ECSRs. Yet, the tasks of ESAS are certainly not limited to organising this conference; further tasks may be the identification of emerging issues for schizophrenia research and, as a consequence, outlining a research agenda and initiation of collaborations and networking activities.

On behalf of the Scientific Committee and the organisers, I cordially welcome you at the 4th European Schizophrenia Research Conference and thank you for your attendance. I wish all of us inspiring days.

Sincerely yours,

Wolfgang GaebelCongress President President European Scientific Association on Schizophrenia and other Psychoses Speaker of the Competence Network on Schizophrenia

5

CONFERENCE ORGANISATION

LOCAL ORGANISERPsychoseNetz e.V.Wolfgang Gaebel, Wolfgang Wölwer, Viktoria Toellerc/o Department of Psychiatry and PsychotherapyHeinrich-Heine-University DüsseldorfLVR Clinic CenterBergische Landstraße 240629 Düsseldorf, Germany

SCIENTIFIC SECRETARIATEuropean Scientific Association on Schizophrenia and other Psychoses (ESAS) e.V.Wolfgang Gaebel, Wolfgang Wölwer, Viktoria Toeller c/o Department of Psychiatry and Psychotherapy Heinrich-Heine-University Düsseldorf, Germany

PROFESSIONAL CONFERENCE ORGANISERHanser & Co GmbHPostfach 12 2122882 Barsbüttel, GermanyPhone: +49 – 40 – 670 88 20Fax: +49 – 40 – 670 32 83Email: [email protected]

SCIENTIFIC PROGRAMME COMMITTEEWolfgang Gaebel, GermanyCongress President

George Awad, CanadaFinn Bengtsson, SwedenDinesh Bhugra, UKGerd Buchkremer, GermanyGeorge Christodoulou, GreecePeter Falkai, GermanySilvana Galderisi, ItalyWagner F. Gattaz, BrazilBirte Glenthoj, DenmarkPhilippe Gorwood, FranceHeinz Häfner, GermanyCyril Höschl, Czech RepublicJoachim Klosterkötter, GermanyValery Krasnov, RussiaShôn Lewis, UKJan Libiger, Czech RepublicWolfgang Maier, GermanyMario Maj, ItalyStephen Marder, USAPatrick McGorry, AustraliaHans-Jürgen Möller, GermanyMerete Nordentoft, DenmarkMichael Owen, UKVictor Peralta, SpainWulf Rössler, SwitzerlandPedro Ruiz, USABernard Sabbe, BelgiumNorman Sartorius, SwitzerlandFrank Schneider, GermanyWolfgang Wölwer, GermanyTil Wykes, UK

ORGANISERS

CO-SPONSORS

World Psychiatric Association (WPA) and its Section on Schizophrenia

WO

RLD


www.wpanet.org

ASIAN NETWORK FOR

SCHIZOPHRENIARESEARCH

Asian Network for Schizophrenia Research (ANSR)

Competence Network on Schizophrenia (CNS)

European Psychiatric Association (EPA) and its Section on Schizophrenia

European Scientific Association on Schizophrenia and other Psychoses (ESAS)

German Association for Psychiatry, Psychotherapy and Psychosomatics (DGPPN)

6

CONFERENCE INFORMATION

CONFERENCE VENUEUrania Berlin e.V.An der Urania 1710787 Berlin, Germany www.urania.de

CONFERENCE REGISTRATION COUNTERAll conference material and documentation are available at the conference registration counter located in the foyer on the ground floor of the Urania.

OPENING HOURSThursday, 26 Sept. 2013 08.00 – 18.00 hFriday, 27 Sept. 2013 08.00 – 19.45 hSaturday, 28 Sept. 2013 08.00 – 16.00 h

During these opening hours the conference counter can be reached at:Phone: +49 – 30 – 2100 81 63

REGISTRATION FEE

ON-SITE REGISTRATION Members of ESAS, CNS, EPA, DGPPN, WPA EUR 490,00Non-members EUR 540,00Trainees * EUR 440,00

* Non-tenured junior scientists or clinical residents in train-ing under 35 years (Trainee status must be confirmed by a certificate in writing by head of department and copy of passport).

ON-SITE REGISTRATIONOn-site registration will be processed on a first-come, first-served basis. Priority will be given to pre-registered delegates. Depending on the num-ber of on-site registered delegates, availability of conference documentation may be limited.

NAME BADGESParticipants are kindly requested to wear their name badge at all times during the conference including the Opening Ceremony and Welcome Reception.

CONFERENCE LANGUAGEThe conference language is English. Simultaneous translation will not be provided.

PROGRAMME CHANGESThe organisers cannot assume liability for any changes in the conference programme due to external or unforeseen circumstances.

CERTIFICATE OF ATTENDANCEA certificate of attendance will be handed out upon demand at the registration counter.

ABSTRACT BOOKAll accepted abstracts are published in an ab-stract book as a supplement of the European Archives of Psychiatry and Clinical Neuro sciences (EAPCN). The abstract book will be handed out to-gether with the conference documentation at the registration counter.

MEDIA CHECKThe Media Check is located in hall Keppler on the first floor of the Urania. Speakers are asked to hand in their CD ROM or USB stick, containing the PowerPoint presentation (IBM format or compa-tible, no multisession) preferably one day before their session but at the latest 90 minutes prior to the presentation. The presentation will be trans-ferred to a special conference notebook in the hall of the presentation. Due to time and technical reasons we kindly ask the speakers not to use their own notebook.

OPENING HOURSThursday, 26 Sept. 2013 08.00 – 18.00 hFriday, 27 Sept. 2013 08.00 – 19.00 hSaturday, 28 Sept. 2013 08.00 – 15.00 h

7

CONFERENCE INFORMATION

POSTER EXHIBITIONThe poster exhibition is located in the foyers on the ground floor of the Urania. Posters will be on display for the entire time of the conference. They will be sorted by topics and will be numbered within those topics.The poster exhibition is open to all registered dele-gates, daily guided poster tours will take place chaired by senior scientists:

Thursday, 26 Sept. 2013Guided Poster Tours P-01 – P-04: 13.30 – 14.30 h

Friday, 27 Sept. 2013Guided Poster Tours P-05 – P-09: 13.30 – 14.30 h

Saturday, 28 Sept. 2013Guided Poster Tours P-10 – P-13: 13.30 – 14.30 h

Interested participants can meet the authors for discussions of their poster presentation during the time of the poster tour.

Set-up and dismantling times for postersSet-up: Thursday, 26 Sept. 2013: 08.00 – 10.00 h

Dismantling:Saturday, 28 Sept. 2013: 16.00 – 17.00 h

Posters which have not been removed within the indicated dismantling time will be disposed.

COFFEE BREAKSCoffee, tea and mineral water will be served free of charge to all registered delegates during the morning and afternoon coffee breaks from Thurs-day, 26 September to Saturday, 28 September 2013. Coffee bar stations are located on the first floor and in the foyer of the ground floor next to the poster exhibition.

LUNCH AND RESTAURANTSA lunch snack will be served to all registered dele gates during the lunch breaks from Thursday, 26 September to Saturday, 28 September 2013 in

the foyer of the ground floor next to the poster exhibition and on the first level. The conference venue further provides a restaurant on the first floor where snacks and food are available on cash basis.

MOBILE PHONESParticipants are kindly requested to keep their mobile phones turned off while attending the scientific sessions in the meeting rooms.

INSURANCEThe conference fee does not include insurance. All participants are advised to arrange for their own insurance. Health and accident insurance is recom-mended and has to be purchased in your country of residence.

HOW TO GET TO THE URANIA: By plane The congress venue Urania is just 8 km from Tegel airport and 22 km from Schönefeld airport.

By train Centrally located within the heart of Berlin close to Tiergarten and Lützowplatz, the Urania is just 5 km from Berlin’s main train station, and only a few minutes by car or taxi.

By car Access to Berlin via the motorways A111, A113 or A115 with direction to Tiergarten / Lützowplatz. The Urania is located in the street “At the Urania”, crossed by the Kurfürstenstrasse.

By public transportationThe Urania is well connected within the public transport network via U-Bahn lines 1, 2, 3 and 4 at the Wittenbergplatz and Nollendorfplatz U-Bahn stations, as well as via bus lines.

PARKINGThe Urania provides 40 parking places free of charge in the courtyard.

8

FORMAT DESCRIPTIONS/ CME CREDITS

The scientifi c programme will comprise the following formats:

PLENARY LECTURESInvited lectures of 45 min each, covering current hot spots in schizophrenia research and given by leading European experts.

SYMPOSIAPre-arranged or submitted symposia of 90 min each, including four presentations and 15 min time for discussion covering major topics of the conference. Both symposia with a clear scientifi c focus and those with a clear clinical focus will be included.

WORKSHOPSPre-arranged workshops allowing for detailed dis-cussion on scientifi c topics in particular serving transnational collaboration within Europe. Par-ticipation is included in the registration fee. For W-01 and W-02 preliminary registration is required.

ORAL PRESENTATION SESSIONSSubmitted presentations grouped by topics into thematic oral sessions of 90 min, including six or seven papers each.

POSTER SESSIONSSubmitted presentations grouped by topics into thematic guided poster sessions.

CME ACCREDITATIONThe ‘European Scientifi c Association on Schizo-phrenia and other Psychoses (ESAS)’ is accredited by the European Accreditation Council for Con-tinuing Medical Education (EACCME) to provide the following CME activity for medical specialists. The EACCME is an institution of the European Union of Medical Specialists (UEMS). www.uems.net. The ‘4th European Conference on Schizophrenia Research (ECSR)’ is designated for a maximum of 16 hours of European external CME credits. Each medical specialist should claim only those hours of credit that he/she actually spent in the educa-tional activity. Through an agreement between the European Union of Medical Specialists and the American Medical Association, physicians may convert EAC-CME credits to an equivalent number of AMA PRA Category 1 Credits™. Information on the process to convert EACCME credit to AMA credit can be found at www.ama-assn.org/go/internationalcme. Live educational activities, occurring outside of Canada, recognised by the UEMS-EACCME for EC-MEC credits are deemed to be Accredited Group Learning Activities (Section 1) as defi ned by the Maintenance of Certifi cation Program of The Roy-al College of Physicians and Surgeons of Canada.

Submit Your Abstract

Abstract Submission Deadline:

1 October 2013

Submit Your Abstract

Abstract Submission Deadline:

1 October 2013

10

OPENING AND WELCOME RECEPTION

09.15 – 10.15 h Humboldt Hall

e Presidential Address Professor Wolfgang Gaebel, Düsseldorf Germany Congress President, Chair of the European Scientific Association on Schizophrenia and other Psychoses (ESAS), Speaker of the Competence Network on Schizophrenia (CNS)

e Welcome Addresses Professor Danuta Wasserman, Stockholm, Sweden President of the European Psychiatric Association (EPA)

Professor Wolfgang Maier, Bonn, Germany President of the German Association for Psychiatry, Psychotherapy and Psychosomatics (DGPPN)

Professor Tarek Okasha, Cairo, Egypt Secretary for Scientific Meetings of the World Psychiatric Association (WPA)

Professor Andi Jayalangkara Tanra, Makassar, Indonesia President of the Asian College for Schizophrenia Research (ACSR)

e Aretaeus-Award Ceremony ! Laureate 2013

Opening Ceremony

Welcome Reception

19.00 – 20.00 h Foyers

At the end of the scientific sessions participants are invited to join the Welcome Reception in the foyers of the first level of the Urania. Finger food and drinks will be provided.

THURSDAY, 26 SEPTEMBER 2013

PL-Plenary Lecture S-Symposium W-Workshop O-Oral Presentation P-Poster

11

Thursday, 26 September 2013 – OVERVIEW

Room

Time Humboldt Kleist Loft A Einstein Loft C Foyer

09.15 –

10.15

Opening Ceremony

Regi

stra

tion

Coun

ter

Open

ing

Hour

s: 08

.00

– 18

.00

10.15 –

11.00

PL-01Toward new ap-proaches to clas-sifying psychotic spectrum disor-ders: the NIMH Research Domain Criteria Project

Coffee Break

11.30 –

13.00

S-01Beyond DSM-5 and ICD-11: how should psychotic disorders be con-ceptualized and diagnosed in the future?

S-02Preventive out-patient treatment approaches for schizophrenia-associated violence and delinquency

S-03Apathy in schizo-phrenia – clinical, experimental and therapeutic ap-proaches

S-04The mild encepha-litis hypothesis of schizophrenia updated: low level neuroinflamma-tion, autoim-munity, volume transmission, treatment ap-proaches

13.00 -

14.30

Lunch Break13.30 – 14.30 h a Guided Poster Tours P-01 to P-04

P-01: Treatment (drug) 1 | P-02: Neuropsychology 1 | P-03: Comorbidity and psychopathology | P-04: Course and outcome

14.30 -

16.00

S-05Approaches for predicting development of psychosis

S-06The risks and benefits of antipsychotic polypharmacy: clinical relevance and development of evidence

S-07Dimensional concepts of psychosis

O-01Neurobiology

W-01: Part 1How to write manuscripts for publication in English language scientific journals

Coffee Break

16.30–

18.00

S-08Biological path-ways to psychosis: the role of stress

S-09Suicide prevention in schizophrenia

S-10Eye movement research: a win-dow to cognitive impairments in schizophrenia?

S-11Microglia in schizophrenia

W-01: Part 2How to write manuscripts for publication in English language scientific journals

18.15–

19.00

PL-02Shifting paradigms for therapeutic discovery

19.00–

20.00Welcome Reception

12

OVERVIEW – Friday, 27 September 2013

Room


08.30 –

10.00

S-12Negative symptoms - impact and thera-peutic options

S-13Progression in brain tissue loss, antipsy-chotic medication, cognition and out-comes in schizophre-nia – the Northern Finland 1966 Birth Cohort Study

S-14Translational genet-ics for psychiatric illnesses

O-02Neuropsychology

Regi

stra

tion

Coun

ter

Open

ing

Hour

s: 08

.00

– 19

.45

Coffee Break

10.30 –

12.00

S-15The future of psychopathology in the light of current neuroscience

S-16New approaches to cognitive behavior therapy for psy-chosis

S-17Epigenetic dysregu-lation in schizo-phrenia

O-03Functional Neuroimaging

12.15 –

13.00

PL-03Structure and func-tion of the human brain at the level of receptors and neural systems: a basis for psychi-atric research

13.00 -

14.30


P-05: Neurobiology and genetics | P-06: Functional neuroimaging | P-07: Research methods and health service research | P-08: Neuropsychology 2 | P-09: Treatment 2

14.30 -

16.00

S-22From structure to functioning: neurobiologi-cal candidates for the prediction of psychoses

S-19Should continuous antipsychotic medi-cation be recom-mended after first episode psychosis?

S-20The role of neu-roinflammation in schizophrenia

S-21Experimental psychopathology of psychosis

W-02How to apply for EU-funding

Coffee Break

16.30–

18.00

S-18Perspectives in schizophrenia research: emerging research issues

S-23Implementation of early intervention services for young people with first episode psychosis: rationale, evidence and practical expe-riences from Europe

S-24Studies using structural and functional neuro-imaging to advance understanding of schizophrenia

O-04Comorbidity

Break

18.15–

19.45

S-25Nosology in the schizophrenic psy-choses: new insight from functional neuroimaging and genetics

S-26The consequences of childhood trauma in psychotic disorders

S-27Progress in neuro-pathological post-mortem findings in schizophrenia

O-05Course and outcome

13

Saturday, 28 September 2013 – OVERVIEW

Room


08.30 –

10.00

S-28The high risk state for psychosis

S-29The role of oli-godendrocytes in schizophrenia: disease-inherent versus treatment-induced abnor-malities

S-30Oscillations and synchrony in corti-cal networks in schizophrenia

O-06Treatment

Regi

stra

tion

Coun

ter

Open

ing

Hour

s: 08

.00

– 16

.00

Coffee Break

10.30 –

12.00

S-31Indicated preven-tion of psychosis

W-03International per-spectives of quality of care and integra-tion of persons with schizophrenia

S-32Single symptom ap-proaches in schizo-phrenia: neuronal correlates of audi-tory hallucinations and language related symptoms

S-33The schizophrenia motor dimension: clinical relevance and neurobiology

12.15 –

13.00

PL-04Twenty years of early interven-tion in psychosis: how critical is the critical period hypothesis?

13.00 -

14.30


P-10: Treatment (psychosocial) 3 | P-11: Risk statesP-12: Structural neuroimaging | P-13: Neuropsychology 3

14.30 -

16.00

S-34Obsessive-compul-sive symptoms in schizophrenia

S-35Psychological treat-ments for people with schizophrenia

S-36Animal models of schizophrenia fac-ing the complexity of genotype, envi-ronmental factors and phenotype

O-07Structural neuroimaging

PL-Plenary Lecture S-Symposium W-Workshop O-Oral Presentation P-Poster

14

SCIENTIFIC PROGRAMME – Thursday, 26 September 2013

PL-01 PLENARY LECTURES10.15 – 11.00 h Humboldt HallToward new approaches to classifying psychotic spectrum disorders: the NIMH Research Domain Criteria ProjectChair: S. Galderisi, Naples, Italy

PL-01-001Toward new approaches to classifying psycho-tic spectrum disorders: the NIMH Research Domain Criteria ProjectB. N. Cuthbert, Bethesda, USA

S-01 SYMPOSIA11.30 – 13.00 h Humboldt HallBeyond DSM-5 and ICD-11: how should psychotic disorders be conceptualized and diagnosed in the future?Chairs: A. Heinz, Berlin, Germany W. Gaebel, Düsseldorf, Germany

S-01-001Functional impairment – a mandatory criterion for mental disorders?W. Gaebel, Düsseldorf, Germany

S-01-002How to distinguish between symptoms of a mental disease and impairments of (social) functionsA. Heinz, Berlin, GermanyE. Friedel

S-01-003Are there specific symptoms that guide schizo-phrenia diagnosis?S. Galderisi, Naples, Italy

S-01-004Can key symptoms of schizophrenia be matched to brain systems?W. Strik, Bern, SwitzerlandT. Dierks

S-02 SYMPOSIA11.30 – 13.00 h Kleist HallPreventive outpatient treatment approaches for schizophrenia-associated violence and delinquencyChairs: C. Luckhaus, Düsseldorf, Germany S. Hodgins, Montreal, Canada

S-02-001The multifactorial basis of violence in schizo-phreniaS. Hodgins, Montreal, Canada

S-02-002A psychoeducational intervention programme to reduce compulsory hospital readmission in the Canton of ZurichB. Lay, Zurich, SwitzerlandT. Schönenberger, M. Bleiker, S. Lengler, C. Blank, W. Rössler

S-02-003A preventive outpatient clinic for high-risk-of-violence patients in the region of Ansbach, BavariaJ. Nitschke, Ansbach, GermanyC. Luckhaus

S-02-004A complex-therapeutic intervention programme for schizophrenia outpatients targeted at re-ducing violent offending and compulsory de-tention in Düsseldorf, North Rhine-WestphaliaC. Luckhaus, Düsseldorf, Germany

15

Thursday, 26 September 2013 – SCIENTIFIC PROGRAMME

S-03 SYMPOSIA11.30 – 13.00 h Loft AApathy in schizophrenia – clinical, experi mental and therapeutic approachesChairs: S. Kaiser, Zurich, Switzerland A. Aleman, Groningen, The Netherlands

S-03-001Apathy in first episode psychosis: similarities and differences to other brain disordersA. Faerden, Oslo, Norway

S-03-002Apathy as a disturbance of motivational and cognitive processes subserving goal-directed behaviorS. Kaiser, Zurich, Switzerland

S-03-003Role of frontostriatal and frontoparietal net-works in apathyA. Aleman, Groningen, The Netherlands

S-03-004Bilateral repetitive transcranial magnetic stim-ulation for negative symptoms of schizophrenia: findings from a double-blind randomized con-trolled trialJ. Dlabac-De Lange, Groningen, The NetherlandsL. Bais, A. Aleman, H. Knegtering

S-04 SYMPOSIA11.30 – 13.00 h Einstein HallThe mild encephalitis hypothesis of schizophrenia updated: low level neuro-inflammation, autoimmunity, volume transmission, treatment approachesChairs: K. Bechter, Guenzburg, Germany B. Lennox, Oxford, United Kingdom

S-04-001Antiinflammation and psychoimmunomodula-tion in schizophreniaE. Weidinger, Munich, GermanyN. Müller

S-04-002Autoimmunity to NMDA receptors in schizo-phreniaB. Lennox, Oxford, United Kingdom

S-04-003Volume transmission balancing wiring (e.g. syn-aptic) transmissionD. Borroto-Escuela, Stockholm, SwedenK. Fuxe

S-04-004The mild encephalitis hypothesis of schizophre-nia updatedK. Bechter, Guenzburg, Germany

16


P-01 POSTER SESSIONS13.30 – 14.30 h FoyerTreatment (drug) 1Chair: W. Fleischhacker, Innsbruck, Austria

P-01-001Bupropion treatment in schizophrenia: Risks and benefits according to the current literatureS. Englisch, Mannheim, GermanyK. Morgen, A. Meyer-Lindenberg, M. Zink

P-01-002Mirtazapine treatment in schizophrenia: evi-dences derived from the current literatureS. Englisch, Mannheim, GermanyF. Afflerbach, M. Zink

P-01-0032-Bromoterguride – an antipsychotic drug?J. Brosda, Berlin, GermanyR. Franke, H. Pertz, H. Fink

P-01-004Use of long acting antipsychotic injections in the maintenance treatment of chronic schizo-phreniaE. Gemma, Terrassa, SpainM. A. Gloria, R. Guillamat, M. Maria, A. M. Fargas

P-01-005Effect of first and second generation antipsy-chotics on face affect expression in German and Chilean patients with schizophreniaV. W. Larach, Santiago, ChileA. Gazmuir, L. F. Varela Espinoza, W. Wölwer, W. Gaebel

P-01-006Adverse metabolic effects associated with use of long acting antipsychotic injections in the maintenance treatment of chronic schizophreniaM. Gloria, Barcelona, SpainG. Español, V. Valles, M. Montoro, A. M. Fargas

P-01-008Descriptive analysis of schizophrenic patients in regular control in an atypical antipsychotic program in ChileA. Armijo, Santiago, ChileJ. Villarroel, F. Valenzuela, D. Castillo, H. Silva

P-01-009Prediction of antipsychotic therapy results bas-ing on GSTM1 gene polymorphism in schizo-phrenic patients with different admission rateV. Obyedkov, Minsk, BelarusO. Skugarevsky, I. Halayenka

P-01-010DTNBP1, HSPs and TAAR6 variations influence schizophrenic phenotype and treatment responseT.-Y. Jun, Seoul, Republic of KoreaC.-U. Pae

P-01-011Neuroleptic malignant syndrome and swan neck deformityE. Neroutsos, Elefsina-Athens, GreeceA. Graikiotis, J. Ntampos, M. Fiste, N. Lytra, E. Thermou

17


P-02 POSTER SESSIONS13.30 – 14.30 h FoyerNeuropsychology 1Chair: M. Green, Sydney, Australia

P-02-001Anticipation and recall of emotions in subclini-cal negative symptoms – an experimental study in a social contextM. Engel, Hamburg, GermanyT. M. Lincoln, A. Fritzsche

P-02-003Different strategies of schizophrenia patients in the visual exploration of social stimuliK. Drusch, Düsseldorf, GermanyS. Stroth, D. Kamp, H. Sievering, N. Raths, C. Schmitz, B. Derntl, W. Wölwer

P-02-004Neurophysiological correlates of defective emo-tional processing in schizophrenic patients with chronic auditory hallucinationsE. Grasa, Barcelona, SpainM. Rabella, S. Martínez-Horta, R. Fernández de Bobadilla, I. Corripio, A. Keymer, F. Artigas, J. San-juán, V. Pérez, J. Riba

P-02-005Neural underpinnings of inhibitory control in schizophrenia patients with a history of vio-lence: a high-density electrical mapping studyG. Andrade, Bronx, New York, USAJ. Butler, M. Krakowski, J. Foxe, P. De Sanctis

P-02-006Early sensory-perceptual contributions to emo-tional processing deficits in schizophrenia pa-tients with a history of violent behaviorW. Ritter, New York, USAP. De Sanctis, G. N. Andrade, J. S. Butler, M. I. Kra-kowski, J. J. Foxe

P-02-007Affectively valenced stimuli modulate different processing stages of the inhibitory control cir-cuit in schizophrenia patients with and without a history of violenceP. De Sanctis, New York, USAJ. J. Foxe, G. N. Andrade, P. Czobor, M. I. Krakowski

P-02-008Metacognitive beliefs and thought control strate gies in early psychosisT. Østefjells, Oslo, NorwayR. Hagen, J. I. Røssberg

P-02-010The integration of evidence is associated with neurocognitive capabilities in schizophreniaS. Eifler, Mannheim, GermanyF. Rausch, F. Schirmbeck, R. Veckenstedt, D. Mier, C. Esslinger, S. Englisch, A. Meyer-Lindenberg, P. Kirsch, M. Zink

P-02-011Interpersonal decentering in patients with schizophreniaK. Hosakova, Bilovec, Czech RepublicM. Lecbych

18


P-03 POSTER SESSIONS13.30 – 14.30 h FoyerComorbidity and psychopathologyChair: W. Strik, Bern, Switzerland

P-03-001Immigrants do not show a specific psychosis symptom profile using a cross-culturally vali-dated model of the PANSSA. Berg, Oslo, NorwayI. Melle, S. R. Aminoff, K. L. Romm, O. Andreassen, E. Hauff

P-03-002Family factor of adaptation of patients with schizophrenic disordersE. Gutkevich, Tomsk, RussiaO. Danilenko, M. Zinchuk, A. Semke

P-03-003Family assessment among patients with various mental disordersH. Sadek, Cairo, EgyptS. Rabei

P-03-004Clinical-dynamic characteristics of schizophre-nia associated with somatic pathologyV. Lebedeva, Tomsk, RussiaA. Semke, E. Yurovskaya

P-03-005Alexithymia is associated with psychotic and hypomanic symptomsM. Joukamaa, Tampere, FinlandS. Luutonen, R. K. Salokangas

P-03-006Megalomania in dementia paralyticaI. Daey Ouwens, Venray, The NetherlandsE. Lens, A. Ott, P. Koehler, W. Verhoeven

P-03-007Schizophrenia-like psychosis and concurrent Substance Abuse: descriptive analysis and phe-nomenological approach in a Colombian inpa-tient early phase rehabilitation programP. Zuleta, Bogotá, ColombiaC. Rodríguez, G. Oviedo, F. Muñoz, J. Navarro

P-03-008Alcohol use in schizophrenic patientsM. Del Carmen García Mahía, A Coruña, SpainE. Roman Fernandez, M. Vidal Millares

P-03-010Prevalence of risk factors in homicidal behavior in schizophrenic patientsI. Aliko, Tirane, AlbaniaA. Kazaferi

19


P-04 POSTER SESSIONS13.30 – 14.30 h FoyerCourse and outcomeChair: V. Larach, Santiago, Chile

P-04-001Duration of untreated psychosis in patients with a first episode psychosis in a high-income-ver-sus a low- and middle income-regionN. Mossaheb, Vienna, AustriaM. Schloegelhofer, R. Kaufmann, S. Werneck-Rohrer, S. Zehetmayer, F. Malik, R. Khawar, H. R. Chaudhry, G. P. Amminger, C. Klier, H. Aschauer

P-04-002Characteristics of illnesses and their course within the „psychotic continuum“ – predictive value for current psychopathology, cognition and functional outcomeJ. Hallaschek, Halle, GermanyS. Watzke

P-04-003Metacognition and negative symptoms in first episode psychosis: cross-sectional and longitu-dinal findingsA. Macbeth, Elgin, United KingdomH. McLeod, A. Gumley, M. Schwannauer, P. Lysaker, G. Dimaggio

P-04-004Comparative of adolescent and adult onset psychosis: one year follow upM. Dolz, Esplugues de Llobregat (BCN), SpainJ. Tor, J. Carlson, B. Sánchez, M. Pardo, D. Muñoz, A. Barajas, I. Baños, J. Usall, S. Ochoa

P-04-006Factors affecting health related quality of life in psychiatric inpatients during treatmentG. Lyrakos, Nikaia, GreeceV. Spinaris, I. Spyropoylos

P-04-008High religiousness, less perspective-taking and social suffering distinguish stable schizophrenia patientsR. Duñó, Sabadell, SpainS. Díaz-Morán, A. Tobeña

P-04-010Schizophrenia with obsessive–compulsive dis-order comorbidity – clinical and treatment par-ticularitiesA. Ciobanu, Bucharest, Romania

20


S-05 SYMPOSIA14.30 – 16.00 h Humboldt HallApproaches for predicting development of psychosisOrganised by the Competence Network on Schizophrenia (CNS)Chairs: M. Marshall, Manchester, United

Kingdom J. Klosterkötter, Cologne, Germany

S-05-001Prognostic and therapeutic validity of the At-tenuated Psychosis SyndromeP. Fusar-Poli, London, United Kingdom

S-05-002The epidemiologic perspective of risk identifi-cation and psychosis predictionI. Kelleher, Dublin, IrelandA. Murtagh, C. Molloy, S. Roddy, M.C. Clark, M. Har-ley, M. Cannon

S-05-003Predicting psychosis in clinical practice–outcome of patients seen in a NHS Prodrome ClinicM. Marshall, Manchester, United KingdomC. Johnson, K. Neelam, R. Drake

S-05-004How to improve the prediction of psychosisS. Ruhrmann, Cologne, Germany

S-06 SYMPOSIA14.30 – 16.00 h Kleist HallThe risks and benefits of antipsychotic polypharmacy: clinical relevance and development of evidenceChairs: J. Cordes, Düsseldorf, Germany W. Fleischhacker, Innsbruck, Austria

S-06-001Antipsychotic drug target occupancy in PET studies: lessons for combining antipsychotics?G. Gründer, Aachen, Germany

S-06-002When to switch or combine: time course for response in antipsychotic drug treatmentM. Jäger, Guenzburg, Germany

S-06-003The development of multiple antipsychotic com-bination treatment in comparison between European countries – findings from the AMSP projectA. Konstantinidis, Vienna, AustriaJ. Cordes, D. Degner, T. Schuhmann, S. Kasper

S-06-004A RCT to assess the benefits of Olanzapine and Amisulpride combination treatment (COMBINE): design and methodsC. Schmidt-Kraepelin, Düsseldorf, Germany

21


S-07 SYMPOSIA14.30 – 16.00 h Loft ADimensional concepts of psychosisChairs: W. Strik, Bern, Switzerland A. Heinz, Berlin, Germany

S-07-001Dimensions of psychotic symptoms and brain physiologyW. Strik, Bern, SwitzerlandS. Walther, A. Wopfner, K. Stegmayer, D. Hubl, H. Horn, T. Dierks

S-07-002Thought and language disorders in psychosisT. Kircher, Marburg, Germany

S-07-003Dysfunctions of the motor system in schizo-phreniaS. Walther, Bern, Switzerland

S-07-004The limbic system and positive symptoms of schizophreniaA. Heinz, Berlin, Germany

W-01 WORKSHOPS14.30 – 18.00 h Loft CHow to write manuscripts for publication in English language scientific journalsChair: S. Hodgins, Montreal, Canada

O-01 ORAL PRESENTATIONS14.30 – 16.00 h Einstein HallNeurobiologyChair: A. Papassotiropoulos, Basel, Switzerland

O-01-001Deviations of levels of serum auto-antibodies (a-Ab) to the antigens of nervous tissue in pa-tients with schizophrenia: confirmation of the mild encephalitis hypothesisV. Orlova, Moscow, RussiaI. Mikhailova, V. Minutko, N. Eliseeva, J. Kretova

O-01-002Evaluation of a potential endophenotype mar ker in schizophrenia: a blunted niacin responseJ. Yao, Pittsburgh, USAG. Dougherty, G. Haas, R. Condray, E. Messamore

O-01-003The role of agmatine in pathogenesis of schizo-phreniaT. Uzbay, Istanbul, TurkeyH. Kayir

O-01-004Reduced striatal adenosine A(2A) receptor levels define a molecular subgroup in schizophreniaM. Barrachina, L´Hospitalet de Llobregat, SpainI. Villar-Menéndez, S. Díaz-Sánchez, M. Blanch, J. L. Albasanz, T. Pereira-Veiga, A. Monje, L. M. Plan-chat, I. Ferrer, M. Martín

O-01-005Correlative multiscale volume microscopy study of white matter cell structures in post-mortem samples of human brainV. Shklover, Skolkovo, Odintsovsky District, RussiaN. Uranova, V. Chelpanov, A. Lavrenyuk, P. Kazanskiy

O-01-006Impact of chronic nicotine treatment on Hip-pocampal Oscillatory Activity in a G72/30 trans-genic mouse model for schizophreniaA. Lundt, Bonn, GermanyB. Hambsch, D.-M. Otte, A. Papazoglou, H. Schrage, D. Mauer, R. Müller, K. Broich, A. Zimmer, M. Weier-gräber

22


S-08 SYMPOSIA16.30 – 18.00 h Humboldt HallBiological pathways to psychosis: the role of stressChairs: D. Nordholm, Copenhagen, Denmark S. Wood, Birmingham, United Kingdom

S-08-001Pituitary volume, cortisol and stress in healthy controls, ultra high-risk subjects and first epi-sode psychosis subjectsD. Nordholm, Copenhagen, DenmarkE. Rostrup, L. Randers, M. O. Nielsen, H. Emig-Norbak, V. Mondelli, P. Dazzan, M. Nordentoft, B. Glenthoj

S-08-002The effect of stress and its biological mediators on the onset and clinical outcome of psychosisV. Mondelli, London, United Kingdom

S-08-003The effect of stress on cortical thickness, surface area and subcortical brain volume in first episode psychosis over the first 12 weeks of treatmentR. Reniers, Birmingham, United Kingdom

S-08-004Effect of pre-exposure to chronic social stress on HPA axis and neurotoxicity in animal models of schizophreniaD. Inta, Mannheim, GermanyD. Filipovic, P. Gass

PL-02 PLENARY LECTURES18.15 – 19.00 h Humboldt HallShifting paradigms for therapeutic dicoveryChair: W. Gaebel, Düsseldorf, Germany

PL-02-001Shifting paradigms for therapeutic discoveryW. T. Carpenter Jr., Baltimore, USA

S-09 SYMPOSIA16.30 – 18.00 h Kleist HallSuicide prevention in schizophreniaChairs: D. Wasserman, Stockholm, Sweden S. Galderisi, Naples, Italy

S-09-001Epidemiology of suicide and attempted suicide in the population of schizophrenic patientsA. Schmidtke, Wuerzburg, GermanyD. Wasserman, B. Pfuhlmann, M. Sarchapione, J. Maloney

S-09-002Psychotic symptoms as a risk marker for sui-cidal behaviourI. Kelleher, Dublin, IrelandP. Corcoran, H. Keeley, J.T.W. Wigman, N. Devlin, H. Ramsay, C. Wasserman, V. Carli, M. Sarchia-pone, C. Hoven, D. Wasserman, M. Cannon

S-09-003Strategies and possibilities in suicide preventionD. Wasserman, Stockholm, Sweden

S-09-004Challenges in clinical practice: predicting, treat-ing and rehabilitating suicidal schizophrenia patientsS. Galderisi, Naples, Italy

23


S-10 SYMPOSIA16.30 – 18.00 h Loft AEye movement research: a window to cognitive impairments in schizophrenia?Chairs: W. Wölwer, Düsseldorf, Germany M. Boucart, Lille, France

S-10-001Independence of smooth pursuit and visual scanpaths and a model of eye movement dys-function in major mental illnessesP. Benson, Aberdeen, United KingdomS. A. Beedie, E. Nouzová, D. St. Clair

S-10-002The relationship between visual exploration and action processing in schizophreniaM. Boucart, Lille, France

S-10-003Gaze behavior in early states of psychosisS. Ruhrmann, Cologne, GermanyA. Nikolaides, S. Miess, R. Müller, J. Klosterkötter

S-10-004Concurrent assessment of eye movements and EEG in schizophreniaS. Stroth, Düsseldorf, GermanyK. Drusch, D. Kamp, W. Wölwer

S-11 SYMPOSIA16.30 – 18.00 h Einstein HallMicroglia in schizophreniaChairs: S. Wolf, Berlin, Germany P. Falkai, Munich, Germany

S-11-001HLA-DR+ microglia are increased in paranoid schizophrenia versus residual schizophrenia: evidence from human postmortem studiesJ. Steiner, Magdeburg, GermanyS. Busse, H.-G. Bernstein, B. Bogerts

S-11-002Immunohistochemical investigations of micro-glia in schizophreniaA. Schmitt, Munich, GermanyT. Bayer, P. Falkai

S-11-003Microglia properties in schizophreniaA. Friebe, Bochum, GermanyG. Juckel

S-11-004Epigenetic changes in microglia derived from an animal model for schizophreniaS. Wolf, Berlin, GermanyD. Mattei

24

SCIENTIFIC PROGRAMME – Friday, 27 September 2013

S-12 SYMPOSIA08.30 – 10.00 h Humboldt HallNegative symptoms – impact and therapeutic optionsChairs: N. Sartorius, Geneva, Switzerland W. Gaebel, Düsseldorf, Germany

S-12-001Negative symptoms in schizophrenia: prevalence and impact on functional outcomeS. Galderisi, Naples, Italy

S-12-002Negative symptoms, culture and the stigma of schizophreniaN. Sartorius, Geneva, Switzerland

S-12-003Current therapeutical options and unmet needs in treating negative symptoms in schizophreniaW. Gaebel, Düsseldorf, Germany

S-12-004Future prospects in the treatment of schizo-phrenia negative symptomsD. Bugarski-Kirola, Switzerland

S-13 SYMPOSIA08.30 – 10.00 h Kleist HallProgression in brain tissue loss, antipsychotic medication, cognition and outcomes in schizophrenia – the Northern Finland 1966 Birth Cohort StudyChairs: J. Miettunen, Oulu, Finland M. Isohanni, Oulu, Finland

S-13-001Outcomes of schizophrenia from a lifespan per-spective – the Northern Finland 1966 Birth Co-hort StudyM. Isohanni, Oulu, FinlandD. Cowling, P. Juola, J. Moilanen, A. Husa, M. Pent-tilä, S. Huhtaniska, J. Veijola, J. Miettunen, E. Jääs-keläinen

S-13-002Antipsychotic medication and longitudinal changes in brain volume in schizophrenia: me-ta-analysis and results from the Northern Fin-land 1966 Birth Cohort StudyJ. Miettunen, Oulu, FinlandS. Huhtaniska, N. Hirvonen, J. Remes, G. Murray, J. Veijola, M. Isohanni, E. Jääskeläinen

S-13-003Longitudinal association between antipsychot-ic medication and change of cognition in schizophrenia – the Northern Finland 1966 Birth Cohort StudyA. Husa, Oulu, FinlandJ. Moilanen, I. Rannikko, M. Haapea, G. Murray, J. Barnett, P. Jones, M. Isohanni, H. Koponen, J. Mi-ettunen, E. Jääskeläinen

S-13-004Duration of untreated psychosis and outcomes and brain volume loss in schizophrenia – the Northern Finland 1966 Birth Cohort StudyM. Penttilä, Oulu, Finland

25

Friday, 27 September 2013 – SCIENTIFIC PROGRAMME

S-14 SYMPOSIA08.30 – 10.00 h Loft ATranslational genetics for psychiatric illnessesOrganised by the German Association for Psychiatry, Psychotherapy and Psychosomatics (DGPPN)Chairs: W. Maier, Bonn, Germany T. Schulze, Göttingen, Germany

S-14-001Genetic mouse models of relevance to schizophre-nia: converging neurobiological mechanisms?J. A. Pratt, Glasgow, United Kingdom

S-14-002The path to translating genetics into clinical psychiatry: a realistic assessmentT. Schulze, Göttingen, Germany

S-14-003Rat models for cognition and cognitive deficitsD. Bartsch, Mannheim, Germany

S-14-004The genetic basis of human memory and its relevance for neuropsychiatric disordersA. Papassotiropoulos, Basel, Switzerland

O-02 ORAL PRESENTATIONS08.30 – 10.00 h Einstein HallNeuropsychologyChair: W. Wölwer, Düsseldorf, Germany

O-02-001Social motor coordination in schizophrenia pa-tients: a new clinical perspectiveD. Capdevielle, Montpellier, FranceR. Salesse, J. Del-Monte, M. Varlet, L. Marin, R. Schmidt, B. Bardy, J.-P. Boulenger, S. Raffard

O-02-002To trust or not to trust: the dynamics of social interactions in early psychosisA.-K. Fett, Amsterdam, The NetherlandsS. S. Shergill, P. M. Gromann, D. W. Joyce, L. Krab-bendam

O-02-003Is the theory of mind deficit in schizophrenia ex plained by an impaired attention toward faces?P. Roux, Paris, FranceB. Forgeot d’Arc, C. Passerieux, F. Ramus

O-02-004To see, or not to see: that is the question. The “Protection-Against-Schizophrenia” (PAS) modelS. Landgraf, Regensburg, Germany

O-02-005Associations between metamemory and neuro-cognitive abilities in schizophreniaS. Eifler, Mannheim, GermanyF. Rausch, F. Schirmbeck, V. Ruth, D. Mier, C. Ess - linger, S. Englisch, A. Meyer-Lindenberg, P. Kirsch, M. Zink

O-02-006The relationship between stress and cognitive performance in real life environments in pa-tients with schizophreniaB. Wright, London, United KingdomE. Peters, E. Kuipers, V. Kumari

26


S-15 SYMPOSIA10.30 – 12.00 h Humboldt HallThe future of psychopathology in the light of current neuroscienceChairs: O. Gruber, Göttingen, Germany W. Gaebel, Düsseldorf, Germany

S-15-001RDoC and the future classification of schizo-phrenia spectrum disordersB. N. Cuthbert, Bethesda, USA

S-15-002Modular psychopathology and symptom dimen-sions in schizophreniaW. Gaebel, Düsseldorf, Germany

S-15-003Neuroimaging of symptoms and endopheno-typic brain dysfunctions in schizophrenia: psy-chopatho(physio)logy of the future?O. Gruber, Göttingen, Germany

S-15-004Symptom dimensions and brain systems: their roles for understanding and treatment of schizophrenia spectrum disordersW. Strik, Bern, SwitzerlandJ. Kindler, P. Homann, A. Wopfner, K. Stegmayer, H. Horn, T. Dierks

PL-03 PLENARY LECTURES12.15 – 13.00 h Humboldt HallStructure and function of the human brain at the level of receptors and neural systems: a basis for psychiatric researchChair: W. Maier, Bonn, Germany

PL-03-001Structure and function of the human brain at the level of receptors and neural systems: a basis for psychiatric researchK. Zilles, Aachen, Germany

S-16 SYMPOSIA10.30 – 12.00 h Kleist HallNew approaches to cognitive behavior therapy for psychosisChairs: T. Kircher, Marburg, Germany J. Klosterkötter, Cologne, Germany

S-16-001Cognitive biases as moderators and mediators of successful CBTpS. Mehl, Marburg, Germany

S-16-002Psychotherapy in subjects at high mental risk stateA. Bechdolf, Berlin, Germany

S-16-003How does CBT effect the brain of patients with schizophrenia: a multicenter fMRI studyA. Krug, Marburg, Germany

S-16-004Who benefits and why? Predictors of change and drop-out during cognitive behavioural therapy for psychosisT. Lincoln, Hamburg, GermanyS. Mehl, S. Westermann, M. Ziegler, M.-L. Kesting, E. Luellmann, W. Rief

27


S-17 SYMPOSIA10.30 – 12.00 h Loft AEpigenetic dysregulation in schizophreniaChairs: P. Falkai, Munich, Germany A. Fischer, Göttingen, Germany

S-17-001Cognitive symptoms in schizophrenia – phar-macological aspects of a core symptom domainW. Fleischhacker, Innsbruck, Austria

S-17-002Molecular basis of epigenetic regulationA. Fischer, Göttingen, Germany

S-17-003HDACi for the treatment of schizophrenia – pre-clinical and clinical aspectsA. Hasan, Munich, Germany

S-17-004Epigenetic therapies in oncology – clinical and safety aspectsM. Bitzer, Tübingen, Germany

O-03 ORAL PRESENTATIONS10.30 – 12.00 h Einstein HallFunctional neuroimagingChair: A. Aleman, Groningen, The Netherlands

O-03-001Phenotyping schizophrenia by multi-modal brain imagingU. Schall, Callagahn, Australia

O-03-002Working memory dependent prefrontal-parietal connectivity and model-based diagnostic clas-sification in schizophreniaL. Deserno, Berlin, GermanyK. H. Brodersen, Z. Lin, W. D. Penny, A. Heinz, K. E. Stephan, F. Schlagenhauf

O-03-003Shared brain phenotypes for working memory dysfunction among schizophrenia and bipolar disorderM. Green, Sydney, AustraliaY. Quide, A. Shepherd, R. Morris, J. Rowland, P. Mit-chell, V. Carr

O-03-004Alterations in the theory of mind network in unaffected first-degree relatives of patients with schizophreniaH. Walter, Berlin, GermanyS. Mohnke, S. Erk, N. Seiferth, O. Grimm, L. Haddad, K. Schnell, M. Nöthen, A. Heinz, A. Meyer-Lindenberg

O-03-005Reduced activation in nucleus accumbens and ventral tegmental area during probabilistic decision-making in schizophreniaF. Rausch, Mannheim, GermanyD. Mier, S. Eifler, C. Esslinger, C. Schilling, F. Schirm-beck, S. Englisch, A. Meyer-Lindenberg, P. Kirsch, M. Zink

O-03-006Abnormal delta oscillatory activity during acute psychotic episode in schizophrenia: a MEG studyJ. Tarrago, Barcelona, SpainR. Novak, C. Alonso, O. Pino, E. Rojo

28


P-05 POSTER SESSIONS13.30 – 14.30 h FoyerNeurobiology and geneticsChair: T. Schulze, Göttingen, Germany

P-05-001Glutamate concentrations and performance during operant conditioning in schizophreniaT. Gleich, Berlin, GermanyR. Böhme, L. Deserno, A. Pankow, J. Gallinat, A. Heinz, F. Schlagenhauf

P-05-002Altered adhesion and microfilament organiza-tion in neuronal precursors of schizophrenia patients: reversion by melatoninG. Benítez-King, México-City, MexicoH. Zamudio-Meza, T. Galvan-Arrieta, A. Riquelme, H. Solís-Chagoyan, J. Muñóz-Estrada, C. Berlanga, I. Meza

P-05-003Neuropathological finding of frontal cortex of animal model and postmortem human brain of schizophreniaS. Iritani, Nagoya, JapanH. Sekiguchi, C. Habuchi, K. Umeda, Y. Torii, M. Mi-yata, K. Fujita, N. Ozaki

P-05-004Molecular mechanisms of visual adaptation: a role for the DTNBP1 (Dysbindin) schizophrenia risk gene in visual short-term plasticityG. Andrade, Bronx, New York, USAJ. Butler, B. Abrahams, J. Foxe

P-05-005Expression of DISC1 in the development of the white matter of ratsC. Li, Chongqing, People‘s Republic of ChinaL. Xiao, S. Liu, M. Wei

P-05-006Role of CB1 receptor and endocannabinoids on cortico-striatal connectivity of psychosocially stressed miceU. Havemann-Reinecke, Göttingen, Germany

P-05-008Concordance and heritability in schizophrenia, register-based data from a Danish twin studyR. Hilker, Glostrup, DenmarkM. Nordentoft, D. Helenius, B. Glenthøj

P-05-009Acute intermittent porphyria and cycloid psy-chosisI. Daey Ouwens, Venray, The Netherlands

P-05-010Kallmann syndrome and schizophrenia: is there a relationship?W. Verhoeven, Venray, The NetherlandsJ. Egger, J. Hovens, N. De Leeuw, L. Hoefsloot

P-05-011Routine screening for copy number variations in schizophrenia-spectrum disorders: relevant to clinical practice?W. Verhoeven, Venray, The NetherlandsN. van de Kerkhof, I. Feenstra, F. van der Heijden, N. de Leeuw, J. Egger, G. Stöber

29


P-06 POSTER SESSIONS13.30 – 14.30 h FoyerFunctional neuroimagingChair: A. Heinz, Berlin, Germany

P-06-001Altered reinforcement learning and working memory in psychosisF. Schlagenhauf, Berlin, Germany

P-06-002Reinforcement learning in an uncertain environ-ment: behavioral and neural correlates in schizophrenia patients and healthy participants with delusional experiencesR. Boehme, Berlin, GermanyL. Deserno, T. Katthagen, A. Pankow, T. Gleich, A. Heinz, F. Schlagenhauf

P-06-003Model-free and model-based control in rein-forcement learning: relation to dopamine syn-thesis and implications for schizophreniaL. Deserno, Berlin, GermanyR. Böhme, A. Wilitzki, R. Buchert, Q. Huys, S. Florian

P-06-004Neural correlates of action and expected value during the anticipation of monetary rewardY. Fukuda, Berlin, GermanyL. Deserno, S. Koch, F. Schlagenhauf

P-06-005Aberrant brain reward response in siblings of patients with psychosis during trust-related behaviourP. Gromann, Amsterdam, The NetherlandsS. Shergill, L. de Haan, D. Meewis, A.-K. Fett, L. Krab-bendam

P-06-006Improvement of brain reward abnormalities related to Dopamine D2/D3 receptor blockade – a study in antipsychotic-naive first-episode schizophrenia patientsS. Wulff, Glostrup, DenmarkM. Ø. Nielsen, E. Rostrup, B. Y. Glenthøj

P-06-007Altered default mode network activity in schizo-phrenia patientsA. Pankow, Berlin, GermanyL. Deserno, F. Bermpohl, M. Walter, F. Schlagen-hauf, A. Heinz

P-06-008Self-reference processing in schizophrenia and psychotic experiences – an fMRI studyT. Katthagen, Berlin, GermanyA. Pankow, L. Deseno, M. Gaebler, A. Heinz, F. Schla-genhauf

P-06-009Brief monocular deprivation as an assay of short-term visual sensory plasticity in schizo-phrenia – “the binocular effect”J. Foxe, Bronx, USAS. Yeap, V. Leavitt

P-06-010Obsessive-compulsive symptoms in schizophre-nia are associated with more activation of the orbito-frontal cortexF. Schirmbeck, Mannheim, GermanyD. Mier, C. Esslinger, F. Rausch, S. Eifler, S. Englisch, A. Meyer-Lindenberg, P. Kirsch, M. Zink

30


P-07 POSTER SESSIONS13.30 – 14.30 h FoyerResearch methods and health service researchChair: to be announced

P-07-002The early recognition inventory ERIraos detects at risk mental states of psychosis with high sensitivityF. Rausch, Mannheim, GermanyS. Eifler, A. Esser, C. Esslinger, F. Schirmbeck, A. Meyer- Lindenberg, M. Zink

P-07-003Assessment of prodromal symptoms in incipient psychotic disorders: reliability and validity mea-sures of the Early Recognition Inventory-Span-ish Version (ERIraos-SV)S. Ochoa, Sant Boi de Llobregat, SpainA. Barajas, A. Farreny, R. Rodriguez-Jimenez, M. Moreno, R. Landin-Romero, C. Bayon, A. Ibanez, B. Cabrera, M. A. Quintanilla, J. Usall

P-07-004“It was easier than dealing with a pen and pa-per...”: exploring the usability of electronic de-vices for completion of Clinical Outcome As-sessments (COAs) in schizophreniaC. Tolley, Bollington, UKD. Rofail, A. Gater

P-07-005When does “Yes” mean “Yes”: is parental con-sent a necessary component of obtaining in-formed consent from minors in Canada’s indig-enous contextC. Cheng, Thunder Bay, CanadaJ. Fogolin, M. Katt, S. Nadin, P. Braunberger, J. B. Minore, C. S. Dewa

P-07-007Changing attitude towards schizophrenia by psychiatric training of medical studentsF. Lang, Guenzburg, GermanyM. Kösters, S. Lang, T. Becker, M. Jäger

P-07-008Assessment on the impact of financial crisis on the access to mental health services in GreeceE. Neroutsos, Elefsina-Athens, GreeceA. Pachi, M. Fiste, E. Kontomina, E. Bisbiki, N. Lytra

P-07-009First Spanish virtual community for people who hear voicesM. J. Escarti Fabra, Valencia, SpainE. Lorente Rovira, A. Luengo Martín, E. Aguilar, J. Sanjuán Arias

P-07-010State and problems of psychiatric care in Kazakhstan (focus on schizophrenia)S. Nurmagambetova, Almaty, KazakhstanM. Assimov

31


P-08 POSTER SESSIONS13.30 – 14.30 h FoyerNeuropsychology 2Chair: P. Ward, Liverpool, Australia

P-08-001Cognitive impairments are linearly related to psychometric risk for schizophrenia-spectrum disordersS. Giakoumaki, Rethymno, GreeceP. Roussos, C. Zouraraki, P. Bitsios

P-08-002Is the tendency to extract meaning from audi-tory noise associated with schizotypy?S. Morton, Dunedin, New ZealandM. Nicolson, R. J. Linscott

P-08-003Schizotypal traits in a community sample: char-acteristics and neuropsychological correlatesM. Tesse, London, United Kingdom

P-08-004Schizotypal traits in a non-clinical population based sample: characteristics and neuropsycho-logical performance profilesM. Tesse, London, United Kingdom

P-08-005Neurocognitive performance in treatment-re-sistant and non-treatment-resistant schizo-phreniaV. Anderson, Auckland, New ZealandM. McIlwain, C. McNabb, R. Kydd, B. Russell

P-08-006Cognitive functioning in individuals aged >65 years with ‘very-late-onset schizophrenia-like-psychosis’ (VLOSLP), chronic schizophrenia and late-onset psychotic depressionS. Simpson, The Ponds, AustraliaR. Langdon, J. Batchelor, A. Falcon, S. Tyagi

P-08-007A comprehensive neuropsychological study of individuals with very-late-onset schizophrenia-like-psychosisS. Simpson, The Ponds, AustraliaR. Langdon, J. Batchelor, A. Falcon, S. Tyagi

P-08-008The relationship between noise-induced stress and cognitive performance in patients with schizophreniaB. Wright, London, United KingdomE. Peters, E. Kuipers, V. Kumari

P-08-009The MATRICS Consensus Cognitive Battery (MCCB) in Norway: associations with IQ, clini-cal and occupational measuresJ. Lystad, Oslo, NorwayE. Falkum, H. Bull, C. Mohn, B. Rishovd Rund, T. Ueland

P-08-010The relation between insight and use of feed-back on the Wisconsin Card Sorting Test in patients with schizophreniaA. de Vos, Assen, The NetherlandsM. Pijnenborg, A. Aleman, L. van der Meer

P-08-011Influence of gender on the primacy and re-cency effect in patients with a first-episode psychosis and schizophrenia patientsE. Huerta-Ramos, Sant Boi de Llobregat, SpainA. Butjosa Molines, C. Núñez Leánez, J. Usall i Rodié, A. Barajas Vélez, A. Foix Sanjuan, M. Dolz Abadia, S. Ochoa Güerre

P-08-013Relation between jumping to conclusions (JTC) and neuropsychological performanceS. Ochoa, Sant Boi de Llobregat, SpainC. Stephan-Otto, L. Nieto, J. Usall, J. Cuevas, E. Huerta-Ramos, J. M. Haro, G. Brebion

32


P-09 POSTER SESSIONS13.30 – 14.30 h FoyerTreatment 2Chair: G. Gründer, Aachen, Germany

P-09-001Sexual adverse effects and antipsychotic-induced hyperprolactinemia: a cross-sectional studyJ. Usall, Sant Boi de Llobregat, SpainR. Cambra, E. Rubio-Abadal, G. Saenz Navarrete, B. Arranz, N. del Cacho, R. Iniesta, M. Roca, V. Barneda

P-09-002Sexual dysfunction in schizophrenic and schizo-affective patients treated with antipsychoticsM. Del Carmen García Mahía, A Coruña, SpainM. Vidal Millares, E. Roman Fernandez

P-09-003Psychiatric and non-psychiatric comorbidity in schizophrenic patients treated with anti-psychoticsM. Del Carmen García Mahía, A Coruña, SpainM. Vidal Millares, J. A. Amado García

P-09-004Comparative assessment of the social perfor-mances for schizophrenic patients treated with long acting antipsychoticsM. C. Pirlog, Craiova, RomaniaI. Marinescu, D. Marinescu

P-09-005Antipsychotics and antidepressants and their associations with suicidal ideation – the North-ern Finland Birth Cohort 1966 studyI. Rissanen, Oulu, FinlandE. Jääskeläinen, M. Isohanni, H. Koponen, M. Jou-kamaa, A. Alaräisänen, J. Miettunen

P-09-006Involuntary hospitalization and the course of medication adherence, treatment engagement and perception of coercionS. Jaeger, Ravensburg, GermanyC. Pfiffner, P. Weiser, G. Längle, D. Croissant, W. Schepp, R. Kilian, T. Becker, G. Eschweiler, T. Steinert

P-09-007Long-term effects of prefrontal rTMS on cogni-tive functioning in schizophreniaC. Kos, Groningen, The NetherlandsJ. Dlabac-de Lange, L. Bais, R. Knegtering, A. Aleman

P-09-008Trends in the administration of electroconvulsive therapy for schizophrenia in Colombia. Descrip-tive study and literature reviewG. Oviedo, Bogotá, ColombiaP. Zuleta, F. Muñoz, C. Torres, R. De la Espriella, D. Garzón, A. Daza, J. Carrillo

P-09-009Sleep prolongation may decrease level of self-reported sleepiness but not slow wave activity in electroencephalogram (EEG) in patients with schizophreniaM. Jarema, Warsaw, PolandL. Okruszek, A. Wichniak, A. Wierzbicka, E. Wali-nowska, K. Czesak, I. Musinska, T. Jakubczyk, W. Jer najczyk M.D.

P-09-010Can work history at baseline predict work be-havior within the first four weeks of vocational rehabilitation?H. Bull, Oslo, NorwayT. Ueland, J. Ullevoldsæter Lystad, E. Falkum

WO

RLD


www.wpanet.org

World Psychiatric Association WPA

European Psychiatric Association EPA

!!!."#$%&'()*$-%+,-*.##-/.*0',.+*-

German Associationfor Psychiatry, Psychotherapyand Psychosomatics

"#$%&'()*$%+,-*.## /.*0',12 – 34 November 1453 | ICC Berlin | Germany

From Therapy to Prevention

SELECTION OF LECTURES| What can Psychiatry contribute to the understanding of extreme violence?

Speaker: Ulrik Malt (Oslo, Norway)

| Mental Health of European youth and scienti6 c evidence for the suicide treatment and preventionSpeaker: Danuta Wasserman (Stockholm, Sweden)

| Future of psychiatric services in the 21st centurySpeaker: Dinesh Bhugra (London, United Kingdom)

| Mental disorders and their care through history in EgyptSpeaker: Tarek A. Okasha (Kairo, Egypt)

| Psychiatric Diagnosis: its past, present, and futureSpeaker: Allen J. Frances (Coronado, USA)

Congress Organiser German Association for Psychiatry, Psychotherapy and Psychosomatics (DGPPN)Reinhardtstraße 27 B | 10117 Berlin | Germany!"#: +49 (0) 30 –240 477 [email protected]

Congress and Exhibition O7 ce

CPO HANSER SERVICE GmbH | O$ ce BerlinPaulsborner Straße 44 | 14193 Berlin | Germany!"#: +49 (0) 30 –300 669 0 [email protected]

| CME certi% ed

| English programme track

WO

RLD


www.wpanet.org

World Psychiatric Association WPA

European Psychiatric Association EPA

!!!."#$%&'()*$-%+,-*.##-/.*0',.+*-

German Associationfor Psychiatry, Psychotherapyand Psychosomatics

"#$%&'()*$%+,-*.## /.*0',12 – 34 November 1453 | ICC Berlin | Germany

From Therapy to Prevention

SELECTION OF LECTURES| What can Psychiatry contribute to the understanding of extreme violence?

Speaker: Ulrik Malt (Oslo, Norway)

| Mental Health of European youth and scienti6 c evidence for the suicide treatment and preventionSpeaker: Danuta Wasserman (Stockholm, Sweden)

| Future of psychiatric services in the 21st centurySpeaker: Dinesh Bhugra (London, United Kingdom)

| Mental disorders and their care through history in EgyptSpeaker: Tarek A. Okasha (Kairo, Egypt)

| Psychiatric Diagnosis: its past, present, and futureSpeaker: Allen J. Frances (Coronado, USA)

Congress Organiser German Association for Psychiatry, Psychotherapy and Psychosomatics (DGPPN)Reinhardtstraße 27 B | 10117 Berlin | Germany!"#: +49 (0) 30 –240 477 [email protected]

Congress and Exhibition O7 ce

CPO HANSER SERVICE GmbH | O$ ce BerlinPaulsborner Straße 44 | 14193 Berlin | Germany!"#: +49 (0) 30 –300 669 0 [email protected]

| CME certi% ed

| English programme track

34


S-22 SYMPOSIA14.30 – 16.00 h Humboldt HallFrom structure to functioning: neurobiological candidates for the prediction of psychosesChairs: S. Ruhrmann, Cologne, Germany S. Wood, Birmingham, United Kingdom

S-22-001The contribution of structural brain imaging to the predcition of psychosesN. Koutsouleris, Munich, Germany

S-22-002The contribution of MR spectroscopy to the prediction of psychosesS. Wood, Birmingham, United Kingdom

S-22-003The contribution of functional imaging to the prediction of psychosesS. Borgwardt, Basel, Switzerland

S-22-004Contributions of cognitive neurophysiology to prediction of psychotic disordersS. Ruhrmann, Cologne, GermanyR. Mueller, M. Bodatsch, J. Klosterkoetter

S-19 SYMPOSIA14.30 – 16.00 h Kleist HallShould continuous antipsychotic medication be recommended after first episode psychosis?Chairs: M. Nordentoft, Copenhagen, Denmark L. Wunderink, Groningen, The

Netherlands

S-19-001Remission of psychotic symptoms and antipsy-chotic medication – long term follow-up of first episode patients included in the TIPS projectI. Melle, Haslum, NorwayJ. I. Røssberg, W. T. Velden Hegelstad, J. H. Evensen, U. Haahr, I. Joa, T. K. Larsen, E. Simonsen, J. O. Jo-hannesen, T. H. McGlashan, S. Friis

S-19-002A focus on poor physical health in psychosis: from animal data to the long-term follow-up of first episode patients from the AESOP studyV. Mondelli, London, United KingdomP. Dazzan

S-19-003Remission of antipsychotic medication and re-mission of psychotic symptoms – long term follow-up of first episode patients included in the OPUS trialM. Nordentoft, Copenhagen, DenmarkS. Austin, O. Mors

S-19-004Recovery in remitted first episode psychosis at 7-years of follow-up of an early dose-reduction/discontinuation or maintenance treatment strategyL. Wunderink, Groningen, The NetherlandsD. Wiersma, S. Sytema, F. Nienhuis

35


S-20 SYMPOSIA14.30 – 16.00 h Loft AThe role of neuroinflammation in schizophreniaChairs: A. J. Tanra, Makassar, Indonesia M. Ohgidani, Fukuoka, Japan

S-20-001Antipsychotics and minocycline as a possible modulator of microglial inflammatory/oxidative stress response in schizophreniaM. Ohgidani, Fukuoka, JapanT. Kato

S-20-002Immature dentate gyrus and mild chronic in-flammation: candidate endophenotype of neu-ropsychiatric disordersT. Miyakawa, Toyoake, Japan

S-20-003Low dose of Dextromethorphan may benefit in schizophrenia treatmentR.-B. Lu, Tainan City, Taiwan

S-20-004The effects of minocycline on microglial cells activation in the dentate gyrus of Gunn rat: a possible animal model of schizophreniaA. J. Tanra, Makassar, Indonesia

W-02 WORKSHOPS14.30 – 16.00 h Loft CHow to apply for EU fundingChair: S. Rauschen, Bonn, Germany

S-21 SYMPOSIA14.30 – 16.00 h Einstein HallExperimental psychopathology of psychosisChairs: M. Voss, Berlin, Germany P. Uhlhaas, Glasgow, United Kingdom

S-21-001Delusions and the role of beliefs in perceptual inferenceP. Sterzer, Berlin, Germany

S-21-002Psychophysical and neurochemical aspects of context perception in schizophreniaJ. Terock, Luebeck, GermanyB. Zurowski

S-21-003Disturbances in the sense of agency in schizo-phreniaM. Voss, Berlin, Germany

S-21-004High-frequency oscillations in schizophrenia: a translational perspectiveP. Uhlhaas, Glasgow, United Kingdom

36


S-18 SYMPOSIA16.30 – 18.00 h Humboldt HallPerspectives in schizophrenia research: emerging research issuesOrganised by the European Scientific Association on Schizophrenia and other Psychoses (ESAS)Chairs: W. Gaebel, Düsseldorf, Germany S. Galderisi, Naples, Italy

S-18-001Emerging research issues in biological and translational researchP. Falkai, Munich, Germany / W. Maier, Bonn, Germany

S-18-002Emerging research issues concerning drug and other somatic treatmentsH.-J. Möller, Munich, Germany

S-18-003Emerging research issues concerning psycho-social interventionsW. Rössler, Zurich, Switzerland

S-18-004Emerging research issues toward recovery: wthe case of negative and cognitive symptomsS. Galderisi, Naples, Italy

S-23 SYMPOSIA16.30 – 18.00 h Kleist HallImplementation of early intervention services for young people with first episode psychosis: rationale, evidence and practical experiences from EuropeChairs: A. Bechdolf, Berlin, Germany M. Birchwood, Birmingham, United

Kingdom

S-23-001Why do we need specialized early intervention in first episode psychosis?A. Bechdolf, Berlin, Germany

S-23-002The early intervention service reform in the UK: outcomes and the next wave of reformM. Birchwood, Birmingham, United Kingdom

S-23-003The EPPIC follow-up study: baseline clinical characteristics and longer-term outcome of first-episode schizophreniaG. P. Amminger, Parkville, Australia

S-23-004Implementation of early intervention services in Denmark – from research to practiceM. Nordentoft, Copenhagen, Denmark

37


S-24 SYMPOSIA16.30 – 18.00 h Loft AStudies using structural and functional neuroimaging to advance understanding of schizophreniaChairs: S. Hodgins, Montreal, Canada B. Schiffer, Bochum, Germany

S-24-001Altered contextual modulation of primary visual cortex responses in schizophreniaP. Sterzer, Berlin, GermanyK. Seymour

S-24-002Mentalizing abilities and their neural under-pinnings in different types of offenders with schizo phreniaB. Schiffer, Bochum, Germany

S-24-003Animacy experience and mentalizing in schizo-phrenic patients who engage in violent offendingC. Pawliczek, Aachen, GermanyB. Schiffer

S-24-004Grey matter density in different types of violent offenders with schizophreniaS. Hodgins, Montreal, CanadaB. Schiffer

O-04 ORAL PRESENTATIONS16.30 – 18.00 h Einstein HallComorbidityChair: N. Sartorius, Geneva, Switzerland

O-04-001The role of striatal dopamine in co-morbid ad-dictive states in schizophrenia – revisiting the „self-medication hypothesis“A. G. Awad, Toronto, Canada

O-04-002The role of substance abuse in prediction of long-term outcome of schizophrenia – system-atic review and meta-analysisJ. Miettunen, Oulu, FinlandK. Kasurinen, N. Hirvonen, E. Oinas, J. Käkelä, E. Jääskeläinen, A. Alaräisänen

O-04-003Is there a relation between reward-disturban-ces and weight gain caused by antipsychotic medication in patients with schizophrenia?M. Nielsen, Roskilde, DenmarkS. Wulff, B. Broberg, E. Rostrup, B. Glenthøj

O-04-004Association between cognitive deficits and obsessive-compulsive symptoms in patients with psychosis and un-affected siblings: a 3 year follow-upF. Schirmbeck, Mannheim, GermanyM. Swets, M. Zink, R. Kahn, J. van Os, R. Brugge-man, W. Cahn, A. Bartels, C. J. Meijer, I. Myin- Germeys, L. de Haan

O-04-005Dissociation and social cognition in schizophre-nia spectrum disorderS. Renard, Groningen, The NetherlandsM. Pijnenborg, P. Lysaker

O-04-006Multimorbidity in psychotic disorders and their unaffected siblings: an epidemiological per-spectiveM. A. Islam, Groningen, The NetherlandsM. F. Khan, P. J. Quee, H. Snieder, E. R. van den Heuvel, R. Bruggeman, B. Z. Alizadeh

38


S-25 SYMPOSIA18.15 – 19.45 h Humboldt HallNosology in the schizophrenic psychoses: new insight from functional neuroimaging and geneticsChairs: B. Pfuhlmann, Wuerzburg, Germany J. Foucher, Strasbourg, France

S-25-001Cycloid psychosis in a Dutch psychiatric teach-ing hospital: relevance for diagnosis, treatment and prognosisW. Verhoeven, Venray, The NetherlandsN. van de Kerkhof, F. Van der Heijden, M. Schneider, G. Stöber

S-25-002Genome-wide search for de novo copy-number variations (CNVs) in cycloid psychoses and chronic schizophrenic psychoses with phenotype correlationM. Gawlik, Cardiff, United KingdomG. Kirov, E. Rees, L. Georgieva, G. Stoeber

S-25-003Functional integration in cycloid psychosis and affect-laden paraphrenia: a double dissociation within the DSM-IV diagnosis of schizophreniaJ. Foucher, Strasbourg, France

S-25-004New genetic loci for periodic catatonia on chro-mosome 7p14.1 and 19p12 in a genome-wide association study with pooled DNAG. Stöber, Wuerzburg, GermanyD. Schanze, A. B. Ekici, B. Pfuhlmann, A. Reis

S-26 SYMPOSIA18.15 – 19.45 h Kleist HallThe consequences of childhood trauma in psychotic disordersChairs: I. Melle, Haslum, Norway M. Aas, Oslo, Norway

S-26-001Childhood trauma and clinical features in bi-polar disorderI. Melle, Haslum, NorwayB. Etain, M. Aas, O. A. Andreassen, F. Bellivier, C. Henry

S-26-002Biological pathways between childhood trauma and psychosis onsetV. Mondelli, London, United Kingdom

S-26-003Trauma and neglect in first episode psychosis: preliminary results 2A. M. Trauelsen, Copenhagen, DenmarkU. H. Haahr, H.-G. Lyse, M. B. Pedersen, J. E. Jansen, E. Simonsen

S-26-004Interactions between BDNF Val66Met, childhood adverse events and brain volume abnormalities in schizophrenia and bipolar disordersM. Aas, Oslo, NorwayU. K. Haukvik, S. Djurovic, Ø. Bergmann, S. Lorentzen, O. A. Andreassen, I. Agartz, I. Melle

39


S-27 SYMPOSIA18.15 – 19.45 h Loft AProgress in neuropathological post-mortem findings in schizophreniaChairs: A. Schmitt, Munich, Germany J. Steiner, Magdeburg, Germany

S-27-001Neuropathological assessment of autopsy cas-es with schizophrenia – recommendations of the Brain Net Europe ConsortiumT. Arzberger, Munich, Germany

S-27-002Histological and gene expression studies of the hippocampus in schizophreniaA. Schmitt, Munich, GermanyH.-G. Bernstein, J. Steiner, C. Schmitz, B. Bogerts, M. Rossner, P. Falkai

S-27-003Oligodendrocytes in schizophreniaJ. Steiner, Magdeburg, GermanyH.-G. Bernstein, B. Bogerts

S-27-004Applying proteomics to schizophrenia post-mortem brain tissueD. Martins-de-Souza, Munich, Germany

O-05 ORAL PRESENTATIONS18.15 – 19.45 h Einstein HallCourse and outcomeChair: V. W. Larach, Santiago, Chile

O-05-001Gender differences in first episode psychosis at five-year follow-up – two different courses of disease?A. Thorup, Copenhagen, DenmarkN. Albert, B. Mette, L. Petersen, P. Jeppesen, P. Le Quarck, M. Nordentoft

O-05-002Association of familial risk to social, occupa-tional and global outcome in schizophrenia – systematic review and meta-analysisJ. Käkelä, Oulu, FinlandE. Oinas, E. Jääskeläinen, J. Miettunen

O-05-003The characteristics of self-experiences and the quality of life in persons with schizophrenia and those after spinal-cord injuryB. Horvat, Velika Polana, Slovenia

O-05-004Quality of life and internalized stigma in pa-tients with schizophrenia: examining the influ-ence of clinical diagnostic and treatment settingS. Oliveira, Lisboa, PortugalF. Esteves

O-05-006 (former O-06-007)Helping people with psychotic disorders back to work – the JUMP studyE. Falkum, Oslo, NorwayJ. Lystad, H. Bull, S. Evensen, T. Ueland

40

SCIENTIFIC PROGRAMME – Saturday, 28 September 2013

S-28 SYMPOSIA08.30 – 10.00 h Humboldt HallThe high risk state for psychosisChairs: J. Klosterkötter, Cologne, Germany P. Fusar-Poli, London, United Kingdom

S-28-001The ultra high risk approach – current state and future directionsP. Fusar-Poli, London, United KingdomA. Yung

S-28-002The basic symptom approach for identifying individuals at high riskJ. Klosterkötter, Cologne, Germany

S-28-003The impact of social functioning and Axis-1 diagnosesR. K. R. Salokangas, Turku, FinlandS. Ruhrmann, H. Graf von Reventlow, M. Heinimaa, S. Luutonen, T. From, G. Juckel, D. Linszen, P. Dingemans, M. Birchwood, P. Patterson, J. Klosterkötter

S-28-004Searching for neuroimaging markers of the high-risk state of psychosisS. Borgwardt, Basel, Switzerland

S-29 SYMPOSIA08.30 – 10.00 h Kleist HallThe role of oligodendrocytes in schizophrenia: disease-inherent versus treatment-induced abnormalitiesChairs: J. Steiner, Magdeburg, Germany N. Uranova, Moscow, Russia

S-29-001Ultrastructural alterations of myelinated fibers and oligodendrocytes in schizophreniaN. Uranova, Moscow, RussiaV. Shklover, O. Vikhreva, V. Rachmanova, D. Orlovskaya, P. Kazanskiy, V. Chelpanov

S-29-002Oligodendrocyte dysfunction in schizophrenia by proteomicsD. Martins-de-Souza, Munich, Germany

S-29-003Animal experiment data regarding the effect of antipsychotic drugs on oligodendrocyte turn-overL. Xiao, Chongqing, People‘s Republic of ChinaH. Wang, J. Niu, H. Wang

S-29-004Protective role of haloperidol and clozapine on energy-deprived oligodendrocytes in cultureJ. Steiner, Magdeburg, GermanyH.-G. Bernstein, B. Bogerts, G. Keilhoff

41

Saturday, 28 September 2013 – SCIENTIFIC PROGRAMME

S-30 SYMPOSIA08.30 – 10.00 h Loft AOscillations and synchrony in cortical networks in schizophreniaJointly organised by the Asian Network for Schizophrenia Research (ANSR) and the European Scientific Association on Schizophrenia and other Psychoses (ESAS) Chairs: J. S. Kwon, Seoul, Republic of Korea S. Ruhrmann, Cologne, Germany

S-30-001Oscillations and synchrony in animal models of schizophreniaT. Sigurdsson, Frankfurt am Main, Germany

S-30-002High-frequency oscillations in schizophrenia: perspectives from MEGP. Uhlhaas, Glasgow, United Kingdom

S-30-003Altered oscillatory activity in the alpha-theta frequency range in schizophrenia patientsR. Müller, Cologne, GermanyS. Ruhrmann

S-30-004Abnormal oscillations and synchrony of MEG in ultra-high risk subjects for psychosisJ. S. Kwon, Seoul, Republic of Korea

O-06 ORAL PRESENTATIONS08.30 – 10.00 h Einstein HallTreatmentChair: A. G. Awad, Toronto, Canada

O-06-001Waiting for godotD. Goel, Invercargill, New Zealand

O-06-002Preliminary results of the Neuroleptic Strategy Study (NeSSy)M. Heinze, Ruedersdorf, GermanyE. Rüther, J. Timm, G. Gründer

O-06-003Working out first-episode schizophrenia: neu-roanatomical, cognitive and clinical changes following an aerobic exercise interventionP. Ward, Liverpool, AustraliaA. Watkins, S. Rosenbaum, J. Lagopoulos, L. Taylor, B. Barry, E. G. Trapp, P. Ward, J. Curtis

O-06-005Does one program look like the other? A sys-tematic review of practices to measure fidelity to early psychosis intervention standardsC. Cheng, Thunder Bay, CanadaA. Selick, J. Durbin, S. Moss

O-06-006Effectiveness of a community-based early in-tervention program for psychosis: baseline characteristics and three-month follow-upJ. Barglow, New York, USAT. Dole, M. Birnbaum

O-06-007 (former O-05-006)Relapses during long-term hospitalization of people suffering from schizophreniaG. Bogojevic, Belgrade, SerbiaD. Zigmund, L. Ziravac, U. Pavic

42


S-31 SYMPOSIA10.30 – 12.00 h Humboldt HallIndicated prevention of psychosisChairs: J. Klosterkötter, Cologne, Germany M. Birchwood, Birmingham, United

Kingdom

S-31-001Interventions in people at high risk of psycho-sis: results of randomized controlled trialsA. Bechdolf, Berlin, Germany

S-31-002Omega-3 fatty acids for indicated prevention: treatment results and pathomechanismsG. P. Amminger, Parkville, AustraliaM. S. Harris, P. D. McGorry, L. P. Henry

S-31-003MindNet: a new model of implementation of early intervention servicesM. Lambert, Hamburg, Germany

S-31-004From risk factors to resilience: perspectives for the prevention of mental disordersS. Ruhrmann, Cologne, Germany

PL-04 PLENARY LECTURES12.15 – 13.00 h Humboldt HallTwenty years of early intervention in psychosis: how critical is the critical period hypothesis?Chair: J. Klosterkötter, Cologne, Germany

PL-04-001Twenty years of early intervention in psychosis: how critical is the critical period hypothesis?M. Birchwood, Birmingham, United Kingdom

W-03 WORKSHOPS10.30 – 12.00 h Kleist HallInternational perspectives of quality of care and integration of persons with schizophreniaJointly organised by the WPA sections on schizophrenia and quality assuranceChairs: A. Javed, Nuneaton, United Kingdom W. Gaebel, Düsseldorf, Germany

W-03-001Long term outcome of schizophrenia in deve-loping and developed countriesN. Sartorius, Geneva, Switzerland

W-03-002Service availability and utilization and treat-ment gap for schizophrenic disorders: a survey in 50 low- and middle income countriesA. Lora, Lecco, Italy

W-03-003The developing countries view on ensuring qual-ity of careA. Javed, Nuneaton, United Kingdom

W-03-004Strategy for management of first psychotic episode supported by state law guarantees in a middle-income countryV. W. Larach, Santiago, Chile

W-03-005Towards a global definition of quality of men-tal healths services – lessons learned from de-veloping a respective EPA guidanceW. Gaebel, Düsseldorf, Germany

43


S-32 SYMPOSIA10.30 – 12.00 h Loft ASingle symptom approaches in schizophrenia: neuronal correlates of auditory hallucinations and language related symptomsChairs: J. Gallinat, Berlin, Germany T. Dierks, Bern, Switzerland

S-32-001Auditory hallucinations and the language systemT. Dierks, Bern, Switzerland

S-32-002Hearing voices as a phenomenon of dyscon-nectivity?C. Mulert, Hamburg, Germany

S-32-003Auditory hallucinations and ego-disturbances: imaging of dysfunctional brain networksJ. Gallinat, Berlin, Germany

S-32-004Non-invasive brain stimulation for the treat-ment of schizophrenia: neurobiological and clinical aspectsA. Hasan, Munich, Germany

S-33 SYMPOSIA10.30 – 12.00 h Einstein HallThe schizophrenia motor dimension: clinical relevance and neurobiologyChairs: S. Walther, Bern, Switzerland M. Morrens, Antwerp, Belgium

S-33-001Parsing the components of psychomotor func-tioning in schizophreniaM. Morrens, Antwerp, Belgium

S-33-002Motor signs in individuals at risk of schizophreniaP. N. van Harten, Maastricht, The Netherlands

S-33-003Clinical and cerebral correlates of neurological soft signs in schizophreniaJ. Schröder, Heidelberg, Germany

S-33-004Dysfunctional subcortico-cortical interactions in the motor loop as probable cause for hypo-kinesia in schizophreniaS. Walther, Bern, Switzerland

44


P-10 POSTER SESSIONS13.30 – 14.30 h FoyerTreatment (psychosocial) 3Chair: T. Lincoln, Hamburg, Germany

P-10-001Metacognitive training for patients with schizo-phrenia: preliminary evidence for a targeted single-module programR. Balzan, Adelaide, AustraliaP. Delfabbro, C. Galletly, T. Woodward

P-10-002Cognitive remediation therapy in schizophreniaM. Fiste, Chaidari-Athens, GreeceM. Papagathaggelou, N. Lytra, E. Thermou, E. Ner-outsos

P-10-003Does the integrated psychological therapy im-prove neurocognition and social-functioning in patients with schizophrenia?A. Taksal, Bangalore, IndiaP. Sudhir, K. Kumar, J. Thirthalli, D. Vishwanath

P-10-004Rehabilitation of communicative abilities in schizophrenic patients through the cognitive pragmatics treatment: a pilot studyF. M. Bosco, Turin, ItalyI. Gabbatore, E. Geda, P. Gastaldo, F. Cauda, R. An-geleri, E. Pirfo, T. Costa, S. Duca, B. G. Bara, K. Sacco

P-10-005Cognitive-behavioral therapy and negative symptoms of schizophreniaM. Fiste, Chaidari-Athens, GreeceE. Neroutsos, N. Lytra, G. Triantafyllou, E. Thermou

P-10-006Effectiveness of group therapy aimed at over-coming schizophreniaA. M. Rojas Rivera, San Antonio, Chile

P-10-007Behavioral Activation for Negative Symptoms (BANS-NL): a nurse intervention for psychotic disordersA. Malda, Leeuwarden, The NetherlandsM. Pijnenborg, N. Boonstra, A. Aleman

P-10-008Comparing psychological interventions of dif-ferent complexities with clinical outcomes in a high risk or psychotic adolescent sampleP. Palombi, Roma, ItalyA. Marconi, G. Colafrancesco, M. Ferrara

P-10-010Competitive work and schizophrenia: design of a project aiming at obtaining and keeping a job through supported employment and multifa-ceted collaborationT. Kivekäs, Helsinki, FinlandK. Ahola, N. Nevala, K.-P. Martimo

45


P-11 POSTER SESSIONS13.30 – 14.30 h FoyerRisk statesChair: A. Bechdolf, Berlin, Germany

P-11-001Perception of neutral and negative stimuli in unaffected first-degree relatives of patients with schizophreniaN. Klaasen, Groningen, The NetherlandsJ. van der Velde, P. Gromann, M. Swart, E. Opmeer, D. Wiersma, R. Bruggeman, L. de Haan, L. Krabben-dam, A. Aleman

P-11-002Emotion recognition as a predictor of transition to a psychotic disorder in ultra-high risk patientsM. Schaefer, Parkville, AustraliaK. Allott, A. Thompson, B. Nelson, S. Bendall, C. Bar-tholomeusz, P. McGorry, M. Schloegelhofer, A. Bechdolf, G. P. Amminger

P-11-003Mothers of schizophrenia patients: features of executive functions and face recognitionN. Khamenka, Minsk, BelarusM. Skuhareuskaya

P-11-004Social cognition, language and social function-ing in children with genetic high risk for devel-oping schizophrenia and bipolar disorderC. J. Christiani, Copenhagen, DenmarkJ. R. Møllegaard Jepsen, A. A. Thorup, N. Hemager, D. V. Ellersgaard, B. K. Burton, A. Ranning, N. O. Mors, K. Plessen, M. Nordentoft

P-11-005Neurocognitive profiles in 7-year-old offspring of parents with schizophrenia or with bipolar disorder – part of the Danish High Risk and Re-silience Study „VIA 7“N. Hemager, Copenhagen, DenmarkJ. R. Møllegaard Jepsen, A. Thorup, C. A. Jerlang Christiani, A. Ranning, B. K. Burton, D. V. Ellers-gaard, M. Skjærbæk, N. P. Ole Mors, M. Nordentoft, K. J. Plessen

P-11-006Psychopathology in offspring of parents with schizophrenia or bipolar disorder – Associations with neurodevelopmental disturbances and childhood stress. Part of the Danish high risk and resilience study – VIA 7D. Ellersgaard, Copenhagen, DenmarkA. Thorup, J. R. Jepsen, B. K. Burton, C. J. Christiani, N. Hemager, M. Skjærbæk, A. Ranning, O. Mors, K. J. Plessen, M. Nordentoft

P-11-007Maturation of mismatch negativity – implica-tions for ultra high risk schizophrenia researchR. Thienel, Waratah, AustraliaR. Fulham, B. Weismueller, N. Hanzon-Kilberg, H. Stain, B. Patch, U. Schall, J. Todd

P-11-008Comparison of two video-based assessments for abnormal motor behavior in adolescents at risk for psychosisS. Schiebler, Bern, SwitzerlandA. Tolev, K. Stegmayer, D. Hubl, W. Strik, F. Schultze-Lutter, B. Schimmelmann, S. Walther

P-11-009Brain activation during self-reflection in ultra-high risk for psychosisE. Opmeer, Groningen, The NetherlandsE. Liemburg, J. van der Velde, R. Nieboer, L. Wun-derink, A. Aleman

P-11-010Formal thought disorder in high-risk for psy-chosis individualsM. Skuhareuskaya, Minsk, BelarusY. Fralova, N. Danilevich, E. Kudina

P-11-011Neurocognition and cathechol-O-methyltrans-ferase Val/Met polymorphism in high-risk for psychosis individualsM. Skuhareuskaya, Minsk, BelarusV. Objedkov, I. Halayenka

46


P-11-012Adolescents at ultra-high risk for psychosis with and without 22q11 deletion syndrome: a com-parsion of prodromal psychotic symptoms and general functioningM. Armando, Rome, ItalyS. Vicari, P. Girardi, D. Menghini, M. Digilio, M. Pontillo, R. Saba, L. Mazzone, A. Lin, M. Schafer, P. Amminger

P-12 POSTER SESSIONS13.30 – 14.30 h FoyerStructural neuroimagingChair: A. Schmitt, Munich, Germany

P-12-001White matter abnormalities in first episode psychosis: a DTI studyT. Melicher, Prague, Czech RepublicP. Mikolas, F. Spaniel, J. Horacek, P. Mohr

P-12-002Processing speed impairment is related to white matter damage in schizophreniaJ. Pena, Bilbao, SpainO. Rilo, N. Ibarretxe, O. Rusu, A. Loizaga, R. Avila, C. Schretlen, M. Varvaris, N. Ojeda

P-12-003White matter pathways of the salience system are altered in schizophreniaT. Bracht, Bern, SwitzerlandH. Horn, W. Strik, A. Federspiel, N. Razavi, K. Steg-mayer, R. Wiest, T. Dierks, T. Mueller, S. Walther

P-12-004Grey matter differences between bipolar pa-tients and controls: a voxel-based morphom-etry meta-analysisR. Ganzola, Quebec, CanadaS. Duchesne

P-12-005Incidental radiological findings on brain mag-netic resonance imaging in patients with first-episode psychosis and healthy controlsI. Falkenberg, Marburg, GermanyS. Benetti, W. Pettersson-Yeo, P. Dazzan, A. Simmons, S. Williams, P. McGuire

P-12-006Structural alterations of the visual system in adolescents with first-admission schizophreniaR. Henze, Heidelberg, GermanyR. Brunner, P. Parzer, M. Freitag, U. Thiemann, F. Resch, B. Stieltjes

P-12-007Alterations of hippocampal volumes and serum BDNF levels in association to atypical antipsy-chotics in a sample of first episode of schizo-phrenic patientsE. Rizos, Athens, GreeceM. Papathanasiou, P. Michalopoulou, E. Laskos, A. Kastania, A. Douzenis, K. Vasilopoulou, I. Liappas

P-12-008Proton MRS findings in the corpus callosum genu and auditory information processing in young male patients with schizophreniaI. Lebedeva, Moscow, RussiaN. Semenova, S. Sidorin, V. Kaleda, A. Barkhatova, T. Akhadov

47


P-13 POSTER SESSIONS13.30 – 14.30 h FoyerNeuropsychology 3Chair: P. Uhlhaas, Glasgow, United Kingdom

P-13-001Spatial cognition in schizophrenia patients mea-sured in virtual reality tests based on animal researchM. Rodriguez, Prague, Czech RepublicI. Fajnerova, K. Vlcek, C. Brom, L. Konradova, K. Dvorska, P. Mikolas, D. Levcik, J. Horacek, A. Stuhlik

P-13-002Mismatch negativity in birdsU. Schall, Callagahn, AustraliaB. Müller, C. Kärgel, O. Güntürkün

P-13-003Sensorimotor learning in stable schizophrenia patients compared to healthy young and el-derly controls in two variations of the rotary pursuitL. De Picker, Antwerp, BelgiumW. Hulstijn, G. Dumont, B. Sabbe

P-13-004A study of Neurological Soft Signs (NSS) in schizophreniaC. S. Gupta, New Delhi, IndiaT. Gupta, S. Pattanayak, S. Aggarwal

P-13-005Predictive value of executive functions impair-ment in early-onset schizophrenia spectrum psychosis: 6 years follow-up studyB. Remberk, Warsaw, PolandA. K. Bazynska, J. Bragoszewska, F. Rybakowski

P-13-007Neurocognitive predictors of symptom severity in first-episode schizophreniaC. Mohn, Drammen, NorwayA.-K. Torgalsbøen

P-13-008Absorption and dissociative detachment, but not compartmentalisation, are associated with psychosis-like experiences in the general pop-ulationC. Humpston, London, United KingdomV. Bell, M. Mehta, Q. Deeley

P-13-009Aberrant salience attribution in schizophrenia patients and healthy participants with delu-sional experiencesS. Diner, Berlin, GermanyA. Pankow, T. Katthagen, S. Koch, L. Deserno, A. Heinz, F. Schlagenhauf

P-13-010Willed actions and mechanisms of initiation, production and control of cognitive responses in schizophrenia: a cue-based protocolR. Rinaldi, Mons, BelarusL. Lefebvre

48


S-34 SYMPOSIA14.30 – 16.00 h Humboldt HallObsessive-compulsive symptoms in schizophreniaChairs: M. Zink, Mannheim, Germany N. Fineberg, Hertfordshire, United

Kingdom

S-34-001Obsessive compulsive symptoms in the early course of psychotic disordersF. Schirmbeck, Mannheim, Germany

S-34-002Neurocognitive differences between schizophre-nia patients with and without comorbid obses-sive-compulsive symptomsN. Fineberg, Hertfordshire, United KingdomD. Patel, K. Mukhopadhaya, K. Laws

S-34-003Antiserotonergic antipsychotics such as cloza-pine induce or aggravate obsessive compulsive symptoms in schizophreniaM. Zink, Mannheim, Germany

S-34-004Effectiveness and outcome predictors of cog-nitive-behavioral therapy for obsessive-com-pulsive disorder co-occurring with psychosisA. Tundo, Rome, ItalyL. Salvati, L. Cieri, M. Daniele, D. Di Spigno, R. Necci, A. Parena

S-35 SYMPOSIA14.30 – 16.00 h Kleist HallPsychological treatments for people with schizophreniaChairs: S. Ochoa, Sant Boi de Llobregat, Spain J. Usall, Sant Boi de Llobregat, Spain

S-35-001REPYFLEC cognitive remediation group training in schizophrenia – looking for an integrative approachJ. Usall, Sant Boi de Llobregat, SpainA. Farreny

S-35-002Metacognitive training in schizophrenia (MCT): immediate, delayed and „sleeper“ effectsS. Moritz, Hamburg, Germany

S-35-003Cognitive-behavioral therapy for people with auditory hallucinationsE. Lorente, Valencia, Spain

S-35-004A randomized, controlled trial of neurocognitive training in schizophreniaM. Linke, Warsaw, PolandM. Jarema, A. Wichniak, K. Jankowski

49


S-36 SYMPOSIA14.30 – 16.00 h Loft AAnimal models of schizophrenia facing the complexity of genotype, environmental factors and phenotypeChairs: R. Wolf, Bochum, Germany M. von Wilmsdorff, Düsseldorf,

Germany

S-36-001Differences in social behavior, prepulse inhibi-tion, dopaminergic and serotonergic hippocam-pal fiber density of CPB-K mice compared to BALB/cJ miceP. Panther, Magdeburg, GermanyS. Nullmeier, A. Kröber, S. Herbert, R. Wolf

S-36-002Pre-treatment with the mGlu2/3 receptor ago-nist LY379268 attenuates DOI-induced impul-sive responding, deficits in prepulse inhibition and regional c-Fos protein expressionL. Wischhof, Bremen, GermanyM. Koch

S-36-003Disturbed gene expression caused by perinatal hypoxia in an animal model of schizophreniaA. Schmitt, Munich, GermanyP. Gebicke-Härter, P. Falkai

S-36-004Sex-dependent metabolic changes caused by drug treatment with haloperidol and clozapine in ratsM. von Wilmsdorff, Düsseldorf, Germany

O-07 ORAL PRESENTATIONS14.30 – 16.00 h Einstein HallStructural neuroimagingChairs: U. Schall, Callagahn, Australia

O-07-001Factors associating to brain volume change in schizophrenia – the Northern Finland 1966 Birth CohortS. Huhtaniska, Oulu, FinlandT.-M. Paaso, M. Kyllönen, J. Moilanen, M. Haapea, G. Murray, P. Jones, J. Miettunen, M. Isohanni, J. Veijola, E. Jääskeläinen

O-07-002Familial and unique environmental influences on brain volumes in twins with schizophreniaM. Picchioni, Northampton, United KingdomT. Toulopoulou, C. Chaddock, J. Cole, U. Ettinger, A. Oses, R. Murray, P. McGuire

O-07-003Greater reductions in grey matter volume in a cognitive-deficit subtype of schizophreniaA. Shepherd, Darlinghurst, Sydney, AustraliaJ. Wong, M. Dragovic, K. Laurens, A. Jablensky, V. Carr, M. Green

O-07-004Supplementary motor area (SMA) volume cor-relates with psychotic symptoms associated with dysregulation of the motor system – A voxel-based morphometry (VBM) studyK. Stegmayer, Bern, SwitzerlandH. Horn, A. Federspiel, N. Razavi, K. Laimböck, T. Bracht, W. Strik, T. Müller, R. Wiest, S. Walther

O-07-005Relevance of posterior parietal areas for audi-tory verbal hallucination in schizophrenia: a voxel-based grey and white matter morpho-metry studyM.-J. van Tol, Gronnigen, The NetherlandsL. van der Meer, R. Bruggeman, G. Modinos, H. Kneg-tering, A. Aleman

O-07-006Structural brain imaging correlates of At-Risk Mental StateU. Schall, Callagahn, AustraliaT. Ehlkes, P. Michie, R. Atkinson, P. Ward

50

FLOOR PLAN

WC WC

WCP

Elevator to Loft A, B, Con level 3

POSTER EXHIBITION

CONFERENCEENTRANCE

FOYER Catering

Registration Cloakroom

Stairs to level 1

POSTER EXHIBITION

URANIA, GROUND FLOOR

g

PWC

WC

Podest

Projektionswand

nnnnnn

HALL HUMBOLDT

HALL KEPLER

HALL EINSTEIN

Cash-Bar

Foyer Catering

HALL KLEISTFoyer

URANIA, FIRST LEVEL

g Media Check

51

FLOORPLAN

Urania – Grundriss 3. OGKleiststraße 13-14, 10787 BerlinDeckenhöhe 3,95 m

M 1:100

Vision Summit 2013Version 2 | Stand: 22.08.2013

Legende

Fläche nicht verfügbar

LOFT C LOFT BLOFT A

Elevator from ground level

Foyer

URANIA, THIRD LEVELLofts A, B and C with access via elevator on ground floor.

The organisers of the 4th European Conference on Schizophrenia Research (ECSR) gratefully acknowledge the support of:

Roche Pharma AG in terms of sponsoring (EUR 10.000)

German Research Association (DFG) in terms of an educational grant

ACKNOWLEDGEMENTS

52

INDEX OF CHAIRPERSONS, AUTHORS AND PRESENTERS

AAas, M. .................................................... 38Aleman, A. .....................................15, 27Aliko, I. ................................................... 18Allott, K. ................................................ 45Amminger, G. P. ..........................36, 42Anderson, V. ........................................ 31Andrade, G. ...................................17, 28Armando, M. ....................................... 46Armijo, A. .............................................. 16Arzberger, T. ......................................... 39Awad, A. G. ...................................37, 41

BBalzan, R. .............................................. 44Barajas, A. ............................................. 30Barglow, J. ............................................ 41Barrachina, M. .................................... 21Bartsch, D. ............................................ 25Bechdolf, A. ...................26, 36, 42, 45Bechter, K. ............................................ 15Benítez-King, G. ................................ 28Benson, P. ............................................. 23Berg, A. .................................................. 18Birchwood, M. .............................36, 42Bitzer, M. .............................................. 27Boehme, R. .......................................... 29Bogojevic, G. ....................................... 41Borgwardt, S. ...............................34, 40Borroto-Escuela, D. .......................... 15Bosco, F. M. .......................................... 44Boucart, M. .......................................... 23Bracht, T. ............................................... 46Brosda, J. .............................................. 16Bugarski-Kirola, D. ............................ 24Bull, H. ................................................... 32

CCapdevielle, D. .................................... 25Carpenter Jr., W. T. ............................ 22Cheng, C. .......................................30, 41Christiani, C. J. .................................... 45Ciobanu, A. .......................................... 19Cordes, J. ............................................... 20Cuthbert, B. N. .............................14, 26

DDaey Ouwens, I. ..........................18, 28De Picker, L. ......................................... 47De Sanctis, P. ....................................... 17Deserno, L. ....................................27, 29de Vos, A. .............................................. 31Dierks, T. ................................................ 43Diner, S. ................................................. 47Dlabac-De Lange, J. .......................... 15Dolz, M. ................................................. 19

Drusch, K. ............................................. 17Duñó, R. ................................................ 19

EEifler, S. ..........................................17, 25Ellersgaard, D. ..................................... 45Engel, M. ............................................... 17Englisch, S. ........................................... 16Escarti Fabra, M. J. ............................ 30

FFaerden, A. ........................................... 15Falkai, P. ................................. 23, 27, 36Falkenberg, I. ....................................... 46Falkum, E. ............................................. 39Farreny, A. ............................................ 48Fett, A.-K. ............................................. 25Fineberg, N. ......................................... 48Fischer, A. ............................................. 27Fiste, M. ................................................. 44Fleischhacker, W. ................ 16, 20, 27Foucher, J. ............................................ 38Foxe, J. ................................................... 29Friebe, A. ............................................... 23Fukuda, Y. ............................................. 29Fusar-Poli, P. ................................20, 40Fuxe, K. .................................................. 15

GGaebel, W. .......14, 22, 24, 26, 36, 42Galderisi, S. ....................14, 22, 24, 36Gallinat, J. ............................................ 43Ganzola, R. ........................................... 46García Mahía, M. Del Carmen .....18, ................................................................... 32Gawlik, M. ............................................ 38Gemma, E. ............................................ 16Giakoumaki, S. ................................... 31Gleich, T. ............................................... 28Gloria, M. .............................................. 16Goel, D. .................................................. 41Graikiotis, A. ........................................ 16Grasa, E. ................................................ 17Green, M. .......................................17, 27Gromann, P. ......................................... 29Gruber, O. ............................................. 26Gründer, G. ...................................20, 32Gupta, C. S. .......................................... 47Gutkevich, E. ....................................... 18

HHallaschek, J. ....................................... 19Hasan, A. ........................................27, 43Havemann-Reinecke, U. ................. 28Heinz, A. ................................. 14, 21, 29Heinze, M. ............................................ 41

Hemager, N. ......................................... 45Henze, R. .............................................. 46Hilker, R. ................................................ 28Hodgins, S. .....................14, 20, 21, 37Horvat, B. ............................................. 39Hosakova, K. ........................................ 17Huerta-Ramos, E. .............................. 31Huhtaniska, S. .................................... 49Humpston, C. ...................................... 47Husa, A. ................................................. 24

IInta, D. ................................................... 22Iritani, S. ............................................... 28Islam, M. A. ........................................... 37Isohanni, M. ........................................ 24

JJaeger, S. ............................................... 32Jäger, M. ............................................... 20Jarema, M. ........................................... 32Javed, A. ................................................ 42Joukamaa, M. ..................................... 18Juckel, G. .............................................. 23Jun, T.-Y. ................................................ 16

KKaiser, S. ................................................ 15Käkelä, J. ............................................... 39Kato, T. ................................................... 35Katthagen, T. ....................................... 29Kelleher, I. ......................................20, 22Khamenka, N. ..................................... 45Khan, M. F. ........................................... 37Kircher, T. .......................................21, 26Kivekäs, T. ............................................. 44Klaasen, N. ........................................... 45Klosterkötter, J. ............20, 26, 40, 42Konstantinidis, A. .............................. 20Kos, C. .................................................... 32Koutsouleris, N. .................................. 34Krug, A. ................................................. 26Kwon, J. S. ............................................ 41

LLambert, M. ......................................... 42Landgraf, S. ......................................... 25Lang, F. .................................................. 30Larach, V. W. ..................16, 19, 39, 42Lay, B. ..................................................... 14Lebedeva, I. .......................................... 46Lebedeva, V. ........................................ 18Lennox, B. ............................................. 15Li, C. ........................................................ 28Lincoln, T. .......................................26, 44Linke, M. ............................................... 48

53

INDEX OF CHAIRPERSONS, AUTHORS AND PRESENTERS

Lora, A. .................................................. 42Lorente, E. ............................................ 48Luckhaus, C. ........................................ 14Lundt, A. ............................................... 21Lu, R.-B. ................................................. 35Lyrakos, G. ............................................ 19Lystad, J. ............................................... 31

MMacbeth, A. ......................................... 19Maier, W. ................................ 25, 26, 36Malda, A. .............................................. 44Marshall, M. ........................................ 20Martins-de-Souza, D. ...............39, 40Mehl, S. ................................................. 26Melicher, T. ........................................... 46Melle, I. ...........................................34, 38Miettunen, J. ................................24, 37Mikhailova, I. ...................................... 21Miyakawa, T. ........................................ 35Mohn, C. ............................................... 47Möller, H.-J. ......................................... 36Mondelli, V. .......................... 22, 34, 38Moritz, S. .............................................. 48Morrens, M. ......................................... 43Morton, S. ............................................ 31Mossaheb, N. ....................................... 19Mulert, C. ............................................. 43Müller, R. .............................................. 41

NNeroutsos, E. ................................16, 30Nielsen, M. ........................................... 37Nitschke, J. ........................................... 14Nordentoft, M. ............................34, 36Nordholm, D. ...................................... 22Nurmagambetova, S. ....................... 30

OObyedkov, V. ........................................ 16Ochoa, S. ................................ 30, 31, 48Ohgidani, M. ....................................... 35Oliveira, S. ............................................ 39Opmeer, E. ............................................ 45Orlova, V. .............................................. 21Østefjells, T. .......................................... 17Oviedo, G. ............................................. 32

PPalombi, P. ........................................... 44Pankow, A. ............................................ 29Panther, P. ............................................ 49Papassotiropoulos, A. ...............21, 25Pawliczek, C. ........................................ 37Pena, J. .................................................. 46

Penttilä, M. .......................................... 24Pfuhlmann, B. ..................................... 38Picchioni, M. ....................................... 49Pirlog, M. C. ......................................... 32Pratt, J. A. ............................................. 25

RRausch, F. ......................................27, 30Rauschen, S. ........................................ 35Remberk, B. ......................................... 47Renard, S. ............................................. 37Reniers, R. ............................................ 22Rilo, O...................................................... 46Rinaldi, R. ............................................. 47Rissanen, I. ........................................... 32Ritter, W. ............................................... 17Rizos, E. ................................................. 46Rodriguez, M. ..................................... 47Rojas Rivera, A. M. ............................ 44Rössler, W. ............................................ 36Roux, P. ................................................. 25Ruhrmann, S. ........ 20, 23, 34, 41, 42

SSadek, H. ............................................... 18Salokangas, R. K. R. .......................... 40Sartorius, N. ......................... 24, 37, 42Schaefer, M. ........................................ 45Schall, U. ................................ 27, 47, 49Schiebler, S. ......................................... 45Schiffer, B. ............................................ 37Schirmbeck, F. ...................... 29, 37, 48Schlagenhauf, F. ................................ 29Schmidtke, A. ...................................... 22Schmidt-Kraepelin, C. ..................... 20Schmitt, A. .....................23, 39, 46, 49Schröder, J. .......................................... 43Schulze, T. ......................................25, 28Shepherd, A. ........................................ 49Shklover, V. .......................................... 21Sigurdsson, T. ...................................... 41Simpson, S. .......................................... 31Skuhareuskaya, M. ............................ 45Spinaris, V. ........................................... 19Stegmayer, K. ...................................... 49Steiner, J. ............................... 23, 39, 40Sterzer, P. .......................................35, 37Stöber, G. .............................................. 38Strik, W. ...........................14, 18, 21, 26Stroth, S. ............................................... 23

TTaksal, A. ............................................... 44Tanra, A. J. ............................................ 35

Tarrago, J. ............................................. 27Terock, J. ............................................... 35Tesse, M. ............................................... 31Thienel, R. ............................................. 45Thorup, A. ............................................. 39Tolley, C. ................................................ 30Trauelsen, A. M. .................................. 38Tundo, A. ............................................... 48

UUhlhaas, P. ............................ 35, 41, 47Uranova, N. .......................................... 40Usall, J. ...........................................32, 48Uzbay, T. ................................................ 21

Vvan Harten, P. N. ............................... 43van Tol, M.-J. ....................................... 49Verhoeven, W. ..............................28, 38von Wilmsdorff, M. .......................... 49Voss, M. ................................................. 35

WWalter, H. .............................................. 27Walther, S. .....................................21, 43Ward, P. ..........................................31, 41Wasserman, D. ................................... 22Weidinger, E. ....................................... 15Wischhof, L. ......................................... 49Wolf, R. ................................................. 49Wolf, S. .................................................. 23Wölwer, W. ....................................23, 25Wood, S. .........................................22, 34Wright, B. ......................................25, 31Wulff, S. ................................................ 29Wunderink, L. ...................................... 34

XXiao, L. ................................................... 40

YYao, J. ..................................................... 21Yung, A. ................................................. 40

ZZilles, K. ................................................. 26Zink, M. ................................................. 48Zuleta, P. ............................................... 18

54

FOR YOUR NOTES

SAVE TIME AND LET THE RESEARCHCOME TO YOU

SIGN UP FOR TABLE OF CONTENTS ALERTS FROM ACTA PSYCHIATRICA SCANDINAVICA

Editor-in-Chief: Povl Munk-Jørgensen, Copenhagen, Denmark

Acta Psychiatrica Scandinavica acts as an international forum for the dissemination of information advancing the science and practice of psychiatry. In particular we focus on ‘translating’ frontline research into useful updating information for the benefit of clinical psychiatry and clinical psychiatric research.

About Table of Contents Alerts from Acta Psychiatrica Scandinavica

Table of Content Alerts are the fastest and easiest way to get to main points of new research. When a new Acta Psychiatrica Scandinavica issue publishes you’ll receive an email notification automatically that features the latest table of contents with links to article abstracts. If your institution subscribes you will be able to access the full-text version of each article.

Best of all, your e-alert registration is available at no cost and completely risk-free. You can opt-out at any time, for any reason – no questions asked. Subscribe for free today!

SAVE TIME AND LET THE RESEARCHCOME TO YOU

SIGN UP FOR TABLE OF CONTENTS ALERTS FROM ACTA PSYCHIATRICA SCANDINAVICA

Editor-in-Chief: Povl Munk-Jørgensen, Copenhagen, Denmark

Acta Psychiatrica Scandinavica acts as an international forum for the dissemination of information advancing the science and practice of psychiatry. In particular we focus on ‘translating’ frontline research into useful updating information for the benefit of clinical psychiatry and clinical psychiatric research.

About Table of Contents Alerts from Acta Psychiatrica Scandinavica

Table of Content Alerts are the fastest and easiest way to get to main points of new research. When a new Acta Psychiatrica Scandinavica issue publishes you’ll receive an email notification automatically that features the latest table of contents with links to article abstracts. If your institution subscribes you will be able to access the full-text version of each article.

Best of all, your e-alert registration is available at no cost and completely risk-free. You can opt-out at any time, for any reason – no questions asked. Subscribe for free today!

13-5

9232

www.schizophrenianet.eu

Documents

4th European Conference on Schizophrenia · PDF fileTogether for better treatment and care ... on Schizophrenia to initiate this biennial European schizophrenia ... Speaker of the